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Abstract 
Cellular therapy to induce islet regeneration is emerging as a novel treatment 
strategy for diabetes. Umbilical cord blood (UCB)-derived hematopoietic stem/progenitor 
cells (HSPC) isolated by high aldehyde dehydrogenase activity (ALDHhi ) reduce 
hyperglycemia after transplantation into streptozotocin (STZ)-treated NOD/SCID mice. 
However, UCB-derived ALDHhi cells are rare and expansion without the loss of 
regenerative function is required. We hypothesized that BMS 493, an inverse retinoic 
acid receptor agonist, will prevent HSPC differentiation of HSPC during expansion, 
generating more ALDHhi cells for therapy. ALDHhi cells expanded for 6 days with BMS 
493 showed a 2.70-fold-increase in ALDHhi cells compared to untreated cells. 
Conditioned media from BMS 493-treated cells also increased human ß-cell proliferation 
in vitro. However, intrapancreatic transplantation of BMS 493-treated cells did not 
reduce hyperglycemia in STZ-treated NOD/SCID mice. Further characterization of 
HSPC expansion without differentiation is required for islet regenerative therapies.  
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1 Introduction 
1.1 Diabetes Mellitus: Incidence and Current Treatments 
            While the majority of the cells in the pancreas are exocrine in nature and aid with 
digestion, 1-2% of pancreatic cells reside in endocrine structures called islets of 
Langerhans. Glucose homeostasis in the body is largely regulated by the hormone insulin, 
secreted by ß-cells within islets. Insulin is a 51-amino acid protein hormone that regulates 
the uptake of glucose into different tissues in the body via the action of insulin-dependent 
glucose transporters GLUT1 and GLUT4(1, 2). Insulin binds an insulin receptor tyrosine 
kinase on peripheral tissue cells leading to autophosphorylation and phosphorylation of 
targets and ultimately leading to translocation of vesicles containing glucose transporters 
to the cell membrane(3). Diabetes mellitus (DM) is a metabolic disorder characterized by 
poor glycemic control leading to excess glucose found in the blood. In contrast, diabetes 
insipidus is caused by a relative decrease in antidiuretic hormone or vasopressin in the 
body leading to polyuria and symptoms similar to those found in patients with diabetes 
mellitus(4). When left uncontrolled, DM can lead to complications including 
cardiovascular disease (CVD), neuropathy, and renal failure(5, 6). 
1.1.1 Type One Diabetes Mellitus 
            There are two main types of DM (referred to as diabetes moving forward) as well 
as several less common types such as gestational diabetes. Type one diabetes mellitus 
(T1DM) is caused by the autoimmune destruction of insulin-producing ß-cells (Figure 
1)(7). T1DM represents approximately 10% of all DM cases and is often referred to as 
early onset or juvenile diabetes(8). Although diagnosis of T1DM is most common during 
childhood, juvenile diabetes can be a misnomer as adults can be diagnosed with 
autoimmune diabetes as well. The incidence of T1DM varies greatly across different 
regions, with highest prevalence in Northern Europe and lowest prevalence in Japan(9-11). 
The lack of insulin production found in T1DM causes chronic hyperglycemia that leads 
to immediate symptoms such as dehydration, polyuria, and ultimately to long term 
complications such as CVD, neuropathy, and nephropathy. While there are genetic 
predispositions for T1DM, including specific HLA-DR and HLA-DQ haplotypes, DM is 
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a multifactorial disease and it is likely that environmental factors such as timing of 
introduction to food and exposure to gestational viruses also play a role(7, 12-14). T-helper 
(CD4+) and cytotoxic T-lymphocytes (CD8+) mediate the destruction of ß-cells via direct 
cell toxicity and autoantibodies generated towards epitopes on ß-cells such as glutamic 
acid decarboxylase (GAD65) and zinc transporter 8 (ZNT8) (8, 15, 16). ß-cell autoantigens 
are presented to B-lymphocytes that produce islet-targeting autoantibodies(17). These 
autoantibodies may or may not present at different stages in the pathogenesis of T1DM, 
but are necessary in the etiology of the disease(18). Cytotoxic (CD8+) T-cells mediate the 
destruction of ß-cells based on autoantigen presentation by B-lymphocytes and dendritic 
antigen presenting cells (15, 17). 
 The discovery of insulin by Sir Frederick Banting in 1921 revolutionized 
treatment for patients with T1DM via exogenous insulin therapy(19). After discovering 
that total pancreatectomy in dogs induced diabetes, Banting and his colleague Charles 
Best set out to find the constituent in pancreatic extracts that allowed the pancreas to 
regulate glucose metabolism. With the help of biochemist James Collip, Banting and Best 
removed digestive enzymes from fetal calf pancreata to isolate a protein that was later 
injected into dogs with diabetes. Only one year following their discovery, insulin was 
injected into the first human with diabetes, 14-year-old Leonard Thompson(20). While 
insulin derived from bovine and porcine sources were commonly used for many years, 
most types of insulin on the market today are synthesized using recombinant DNA 
technology produced in bacteria or yeast(21, 22). 
There are several different types of insulin that can be used alone or in 
combination. Insulin is categorized based on its mode of action ranging from rapid-acting 
insulin aspart to long-acting insulin glargine(23). The difference in a single amino acid can 
change the onset of action or duration of the insulin. The two main methods of insulin 
delivery in patients with T1DM are multiple daily injections or continuous insulin 
delivery through an infusion pump. Regardless of the type of insulin delivery, glucose 
homeostasis remains problematic with the potential for life-threatening hypo and 
hyperglycemic events as well as risk of diabetic ketoacidosis. Due to the peaks and 
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troughs in glucose metabolism over time, patients with T1DM are at risk for many 
complications including cardiovascular disease, nephropathy, and neuropathy.  
1.1.2 Type Two Diabetes Mellitus 
 In contrast to T1DM, T2DM is a metabolic disorder where patients usually 
experience peripheral insulin resistance, the inability of tissues such as muscle to 
efficiently respond to insulin and excess glucose found in the blood (Figure 1.1)(24). 
T2DM represents over 90% of all patients with diabetes, with prevalence increasing to 
epidemic rates due to an aging population demographic and increasing rates of obesity(8, 
25). As stated by the American Diabetes Association, inability to respond to insulin can 
result in both pathological and physiological changes in the peripheral tissues over 
time(26). Insulin resistance can lead to a loss of ß-cell mass and decreased production of 
insulin over time, although there is no autoimmune destruction of pancreatic ß-cells as 
seen in T1DM. Surprisingly, there is a greater genetic predisposition to T2DM than 
T1DM, though many patients with the disease are considered obese and live a sedentary 
lifestyle(27). While some patients can reduce or even reverse the symptoms of 
hyperglycemia by exercise and weight loss, there are several different classes of drugs 
that can be used to treat T2DM, generally mediated by increasing insulin availability in 
peripheral tissue or reducing glucose reuptake in the kidneys. Some of the most widely 
used drugs are metformin, sulfonylureas, thiazolidinediones, and glucagon-like peptide 1 
(GLP-1) inhibitors. Metformin reduces the liver’s conversion of stored glycogen to 
readily available glucose, while drugs such as sulfonylureas and thiazolidinediones act 
directly to increase insulin secretion from the pancreas or increase insulin sensitivity by 
peripheral tissues, respectively(28). More recently, SGLT2 inhibitors such as 
empagliflozin have been used in patients with T2DM. This class of drugs act by 
inhibiting glucose co-transporters in the kidney, thus preventing the reabsorption of 
glucose(29). Ultimately, patients with T2DM may require exogenous insulin to meet the 
metabolic demands of the body. Both T1DM and T2DM together raise a serious health 
care concern and huge economic burden due to the development of severe, chronic 
complications. 
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Figure 1.1. Underlying cellular mechanisms behind T1DM and T2DM. Schematic 
showing the differing pathophysiology of the two main types of DM. In T1DM patients, 
autoimmune destruction of the ß-cells in the pancreas prevents endogenous insulin 
production leading a lack of insulin-dependent glucose uptake in peripheral tissue cells. 
In T2DM patients, machinery for endogenous insulin production in the pancreas is intact; 
however, peripheral tissue cells are unable to respond to insulin. Both T1DM and T2DM 
lead to chronic hyperglycemia over time. 
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1.1.3 Prevalence of Diabetes  
In 2016, the International Diabetes Federation estimated there were over 400 
million people worldwide living with diabetes and this number is expected to increase to 
642 million by the year 2040. The global cost of diabetes including treatments, 
prevention strategies, and complications is over 600 billion USD with countries spending 
up to 20% of their health care costs on diabetes alone. In 2012, the United States was 
estimated to have spent over 245 billion USD on diabetes and diabetes related costs(25). 
Current treatment options remain inadequate, resulting in glucose fluctuations and 
patients often require extremely regimented schedules for medication. Thus, there is a 
desperate need to develop more curative therapies for patients with both type 1 and type 2 
diabetes to reduce co-morbidities and the associated complications. 
1.2 Complications of Diabetes 
Regardless of the type of diabetes, prolonged hyperglycemia in the body can lead 
to several long-term complications of the cardiovascular system. These are divided into 
two main groups, microvascular and macrovascular complications, and both groups of 
complications are attributed to the effects of excess glucose on the blood vessels found in 
different parts of the body. Microvascular complications converge on the endothelial cell 
lining of blood vessels that regulate vascular processes such as dilation and contraction 
and transportation of nutrients by producing bioactive compounds such as nitric oxide 
(NO) and angiotensin II(30). Excess glucose found in the blood stream of patients with 
DM can be toxic to the endothelium and its signaling processes. For example, when the 
response to different vasoconstrictors and vasodilators was tested, T1DM patients had 
impaired NO-mediated vasodilation compared to non-diabetic controls and similar results 
were seen in patients with T2DM(31). Hyperglycemia can also block the action of 
endothelial nitric oxide synthase (eNOS), the enzyme responsible for producing NO. 
Interestingly, there was no difference between patients with DM and non-diabetic 
individuals in the response to vasodilators such as verapamil that act on smooth muscle 
cells instead of endothelial cells(32). Collectively, these studies give evidence that chronic 
hyperglycemia found in patients with DM adversely affects endothelial cells and their 
signaling mechanisms. Damage to the microvasculature is responsible for complications 
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such as retinopathy, neuropathy, and nephropathy. In the United States, for example, 
diabetic nephropathy is the leading cause of renal failure.  
Macrovascular complications, such as atherosclerotic cardiovascular disease 
(CVD), represent the primary cause of death in patients with both T1DM and T2DM. In 
fact, T1DM patients are 2 – 5 times more likely to be diagnosed with CVD than non-
diabetic individuals(33). Advanced atherosclerosis is defined as fibrous plaques found in 
the vasculature that are often surrounded by smooth muscle cells and connective tissue 
and contain variable amounts and types of lipids(34). Atherosclerosis is the main cause of 
macrovascular complications, although it is not fully understood why diabetic patients are 
at a greater risk. For T2DM patients, the greater risk of macrovascular CVD can be in 
part explained by the fact that most patients are also facing other risk factors such as 
obesity and dyslipidemia. However, blood pressure is often monitored in patients with 
diabetes and drug therapy such as ACE inhibitors are often prescribed as a precautionary 
measure to avoid hypertension, another risk factor for atherosclerosis(35). Statins and anti-
inflammatories are also prescribed to prevent the development of atherosclerosis in 
patients with T2DM(36). Furthermore, studies have shown that improved glycemic control 
in patients with T1DM can reduce the risk of macrovascular complications. 
There are many proposed mechanisms to explain cell injury and progression of 
both macrovascular and microvascular diseases in patients with DM. One pathway that 
has been extensively studied is the polyol pathway(35, 37). Aldose reductase is used to 
convert excess glucose into inactive alcohols or sorbitol. Increased flux of glucose 
through this pathway can increase reactive oxygen species and decrease reduced 
glutathione, which acts as an intracellular antioxidant. These outcomes are associated 
with alterations in basement membranes and the number of pericytes surrounding vessels. 
The accumulation of advanced glycosylation end-products (AGE) and their role in 
microvascular diseases have also been heavily studied. AGE describe a group of 
compounds formed when reducing sugars react with proteins or lipids and patients with 
DM have a high susceptibility of accumulating AGE(35, 38). Damage to specific proteins 
associated with different microvascular diseases have been attributed to the formation of 
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AGE(39). Regardless of the mechanisms at play, chronic hyperglycemia found in DM 
negatively impacts the endothelium, resulting in serious, life-threatening complications. 
1.3 Islet Replacement Strategies for Treating Diabetes 
Whole pancreas transplantation has been studied in T1DM patients who are 
concurrently receiving a kidney transplant due to renal failure(40). Although this 
procedure is rare due to the difficult surgical procedure and a high risk of complications, 
much was learned from the clinical outcomes of these studies(41). Survival rates of 
patients 1-year post transplantation were high with good pancreas engraftment, although 
patients did require immunosuppressive therapy(42).  Overall, pancreas transplantation is 
considered extremely risky and is not a recommended treatment for the majority of 
patients with DM. 
In the year 2000, a Canadian group lead by James Shapiro was the first to 
transplant cadaveric islets into brittle T1DM patients, a trial commonly known as the 
Edmonton Protocol. Patients received immunosuppressive therapies including sirlimus, 
tacrolimus, and daclizumab before hepatic portal vein transplantation of 11,547±1604 
islet equivalents per kilogram of body weight(43). Of the seven patients enrolled in the 
initial trial, all remained free of exogenous insulin for a minimum of one year, a result 
that was found to be promising. However, as the trial expanded, there were several acute 
complications, patients required immunosuppressant agents, and low engraftment levels 
as islets were transplanted into the liver(44, 45). Moreover, the transplants failed over time 
with the requirement for exogenous insulin returning. Ultimately, there is an immense 
shortage of cadaveric donors to treat T1DM patients, with each patient needing an 
average of two donors. Despite these shortcomings, the Edmonton Protocol was 
important in establishing proof of concept that islet transplantation could reduce 
hyperglycemia in patients with brittle T1DM. 
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1.4 Stem Cell Types Relevant to Diabetes Therapy 
Stem cells may represent a powerful approach for the development of a curative 
therapy as there is a need for an unlimited source of ß-cells to treat T1DM. Pioneering 
experiments and the discovery of stem cells came from two Canadian scientists James 
Till and Earnest McCulloch in 1961(46). Till and McCulloch established that stem cells 
have two founding properties: the ability to self-renew and to differentiate to more 
specified, committed cell type. In particular, Till and McCulloch studied the capacity of 
murine bone marrow (BM) cells to reconstitute the hematopoietic system in supralethally 
irradiated host mice after intravenous (IV) transplantation. They noticed that there was a 
correlation between the number of mice that survived treatment and the dose of BM cells 
that was transplanted. They also observed that mice were less likely to survive if the 
donor BM cells were irradiated prior to transplantation. Interestingly, they analyzed 
hematopoietic colonies, or nodules, that formed in the spleen of mice and suggested that 
the progeny of these cells migrated to hematopoietic organs such as the BM, where they 
were able to engraft and proliferate. Their observation is an example of tissue-resident 
adult stem cells; however, the field has advanced and various sources of stem cells with 
distinct functional capacities are used in research today. 
There are three broad categories of human stem cells: adult stem cells, embryonic 
stem (ES) cells, and induced pluripotent stem (iPS) cells. Although the use of ES cells is 
controversial and raises ethical issues, they arguably represent the most powerful of the 
three stem cell populations. hES cell lines were first derived by James Thompson in 
1998(47). hES cells were derived from the inner cell mass of the blastocyst. hES cell lines 
are typically derived from excess blastocysts generated by in vitro fertilization clinics. 
During development, three germ layers that form the entire organism are derived from the 
cells within the inner cell mass: endoderm, ectoderm, and mesoderm. Thus, ES cells from 
the inner cell mass retain the capacity to generate any cell type in the body and are 
referred to as pluripotent. ß-cell replacement therapies using differentiated hES cells to 
treat DM are currently underway and are further discussed in section 1.5.1. 
iPS cells allow researchers to revert mature cell types back to pluripotent cells using a 
cocktail of transcription factors, commonly known as Yamanaka factors. In 2006, 
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Takahashi and Yamanaka were able to convert adult mouse fibroblasts into ES-like cells 
using Oct3/4, Sox2, c-Myc, and Klf4(48). These four transcription factors had been shown 
to play a role in maintaining pluripotency in ES cells, and additionally, mouse iPS cells 
from fibroblasts displayed teratoma formation when transplanted into healthy mice. The 
use of iPS cells in therapies would allow for autologous pluripotent cell transplantation, 
with patients having the ability to receive stem cells derived from their own somatic cells, 
overcoming the need for aggressive immunosuppressive therapy. That being said, while 
there have been preclinical trials using iPS cells for the treatment of diabetes, there are 
currently no clinical trials due to the potential risk of tumor formation during the 
reprogramming process(49-51). Precise and efficient differentiation of iPS cells into ß-cells 
must be ensured before iPS cells can be implemented in clinical trials. 
1.5 Cellular Therapies for Diabetes 
Cellular therapies are emerging as a novel treatment strategy for patients with 
diabetes. These strategies are often divided into two categories, replacement therapies 
and regenerative therapies. Replacement therapies have focused on increasing insulin 
supply by transplantation of cadaveric islets or stem cells that have been differentiated 
into ß-like cells. Several groups have mimicked in vivo differentiation of ß-cells during 
development and have used a cocktail of cytokines or transcription factors to direct the 
differentiation of pluripotent hES cells into ß-cells that are able to produce levels of 
insulin similar to those produced by healthy individuals. These protocols are extremely 
specific and somewhat inefficient, but effectively differentiate cells from definitive 
endoderm to committed endocrine progenitor. While the directed differentiation of ß-
cells from hES cells or iPS cells is quite well understood, these therapies have yet to 
overcome the hurdle of autoimmunity found in T1DM, making patients susceptible to the 
same immune attack and often in need of immunosuppressant therapies.  
1.5.1 Cell Types Involved in Islet Replacement Therapies 
Research has tried to mimic developmental signals during embryogenesis to 
differentiate iPS and hES into insulin producing cells that can be transplanted into 
patients with diabetes. During organogenesis, the entire pancreas including exocrine, 
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endocrine, and ductal epithelial cells is derived from definitive endoderm. After the 
definitive endoderm has formed the primitive streak, differentiation of various pancreatic 
cell types are driven by the presence or absence of many transcription factors. For 
example, all cells in the developing pancreas express pancreatic and duodenal homeobox 
1 (Pdx1), but only properly differentiated, mature ß-cells co-express homeobox protein 
Nkx-6.1, homeobox protein Nkx-2.2, and most importantly, insulin. D’Amour et al. first 
established a protocol to generate endocrine cells from hES cells(52). While they were able 
to differentiate hES into hormone positive cells in vitro, these cells were poorly glucose 
responsive. When the same group transplanted these cells into streptozotocin-treated 
(STZ) NOD/SCID mice, after 16 weeks they were able to detect c-peptide and insulin 
release in response to a glucose load(53). More recently, Timothy Kieffer’s group has 
derived insulin producing cells from other sources such as K cells in the digestive tract. 
These cells are already glucose-responsive in their release of gastric inhibitory 
polypeptide and can be engineered to secrete insulin(54). Additionally, these cells may be 
able to escape the autoimmune attack found in patients with T1DM. Unfortunately, 
producing glucose responsive ß-cells is only the first hurdle in creating a stem cell 
replacement therapy to treat diabetes. 
 More recently, groups have been working on the transplantation of further 
differentiated ß-cells from both ES and iPS cell sources within encapsulation devices. An 
encapsulation device can allow protection from the immune system of patients with 
T1DM while allowing insulin to be secreted into nearby vasculature. These devices are 
often transplanted under the skin and thus can easily be removed or replaced. Clinical 
trials are ongoing; however, there are still many hurdles to overcome such as reducing the 
number of encapsulation devices needed to obtain sufficient serum insulin levels, 
ensuring adequate vascularization of these devices for efficient insulin delivery 
throughout the body, and prevention of device directed inflammatory response due to 
continued autoimmune attack. Although replacement strategies are leading in the clinic, 
this thesis focuses on the induction of islet regeneration in situ using regeneration 
initiating cell therapy. 
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1.5.2 Cell Types Involved in Endogenous Islet Regeneration 
In 2010, a study conducted by Keenan et al. looked at a cohort from this study 
were extremely surprising. Firstly, 67% of patients in the study had detectable c-peptide 
levels, a by-product of endogenous human insulin production. Notably, c-peptide levels 
were assumed to be underestimated as exogenous insulin was continually administered 
and patients were not stimulated to secrete insulin. Secondly, post-mortem analysis was 
conducted on the pancreata of several Medalists. All pancreata studied showed the 
presence of insulin positive cells, although these cells were not usually detected in islet-
like structures. Finally, histological analysis on the pancreata of several patients 
contained insulin positive, Ki67 positive cells, indicating proliferation of ß-cells within 
the pancreas in the face of ongoing autoimmunity. These results were the first to suggest 
that patients with T1DM possess residual ß-cell function and low-levels of insulin 
production despite ongoing autoimmune attack. Therefore, endogenous islet repair may 
prove to be a potential mechanism to increase ß-cell mass in situ. Thus, the Medalist 
study provided rationale for the study of regeneration inducing therapies combined with 
the dampening of autoimmunity as a new strategy for treatment of diabetes. 
Most organs in the adult human body contain rare tissue resident stem cells with some 
capacity to regenerate. Organs such as the liver and intestine show high cell turnover 
rates and high regenerative capacity while other organs such as the brain and the 
endocrine pancreas show extremely low cell turnover. Although stem cell populations 
reside in many organ systems throughout the body, some of which are more easily 
accessible or renewable and can be used with little ethical controversy. Two sources of 
adult stem cells that have been heavily researched in the context of therapies for diabetes 
are BM and umbilical cord blood (UCB). Since Till and McCulloch’s discovery in 1961, 
two types of stem cells found in BM that have been highly studied: (1) multipotent 
stromal cells (MSC) that have the ability to differentiate into osteocytes, chondrocytes, 
and adipocytes and (2) hematopoietic stem cells (HSC) that have the ability to form the 
mature cell types found in blood. Similarly, UCB is rich in HSC and MSC, and provides 
a readily available supply of cells for the development of cell therapies. Interestingly, it is 
becoming increasingly popular for families to bank UCB either publically or privately for 
  
12 
use in the future. The potential for adult stem cells for novel human cell therapies has 
attracted much attention in preclinical studies. 
There have been several preclinical trials conducted using BM-derived cells for 
the induction of islet regeneration in diabetic recipients(55-57). In 2003, Ianus et al. was 
one of the first groups to publish studies using BM-derived cells in the context of 
diabetes(58). BM cells isolated from male mice were labeled with eGFP in a Cre-Lox 
system activated by insulin gene expression. Irradiated female mice received 
approximately 1x106 BM through tail vein injection. Following transplantation, Y-
chromosome, eGFP+ cells were isolated from pancreatic islets that co-expressed insulin 
and GLUT2. Collectively, these findings suggested that BM cells were able to 
transdifferentiate into ß-cells after transplantation in vivo. However, other groups 
studying the effect of BM-derived cells on the pancreas were unable to recapitulate the 
rare transdifferentiation events observed by findings of Ianus et al. 
Choi et al. transplanted BM-derived cells into recipient hyperglycemic mice that 
received low dose STZ for 5 days(59). Although the cellular transplants contained a mix of 
primitive and mature hematopoietic cells and MSC, after 5 weeks, mice blood glucose 
levels and insulin secretion recovered at almost normal levels. GFP transgenic mice 
provided BM cells that were used to trace donor cells engrafting in the pancreas and it 
was concluded that there was no transdifferentiation of BM cells to insulin positive islet 
cells. Alternatively, the functional response was stimulated by donor cells inducing islet 
regeneration. Also in 2003, Hess et al. showed that BM-derived hematopoietic 
stem/progenitor cells (HSPC) isolated based on c-kit expression, a marker of murine 
HSPC, were able to reduce hyperglycemia in STZ-treated NOD/SCID mice after 
transplantation(57). Again, few of the donor cells were insulin positive and GFP+/insulin+ 
cells were not present at the time of glucose reduction, strengthening the argument that 
this cell population can play a role inducing endogenous islet regeneration. BM continued 
to be a popular source of cells for regenerative therapies for diabetes since, in addition to 
the aforementioned islet regenerative properties of BM cells, many groups have also 
studied the immunosuppressive properties of BM cell populations. 
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Later, Matthews et al. studied the role of BM-derived endothelial progenitor cells 
(EPC) that respond to STZ-induced pancreatic injury. While these studies did not 
increase the loss of ß-cell mass induced by STZ-treatment, they were able to show that 
BM-derived EPC could be recruited to the site of tissue injury (pancreas) and could aid in 
vascularization of the injured tissue(60). Not only did transplanted BM-derived EPC play a 
role in pancreas vascularization, but resident EPC were activated to take part in 
endogenous islet repair. In 2006, Lee et al. demonstrated that human BM-derived MSC 
could reduce STZ-induced hyperglycemia in NOD/SCID mice after intracardiac infusion 
on two separate occasions(61). Serum insulin concentration was increased in mice 
transplanted with MSC compared to controls, and while human cells were detected in the 
islets on occasion, human insulin was not detected by ELISA. Urban et al. looked at the 
immunosuppressive qualities of BM-derived MSC in treating diabetes(62). BM cells were 
able to reduce hyperglycemia in STZ-induced hyperglycemic mice, but the authors 
suggested that MSC could also play an immune-protective role from the cytotoxic CD8+ 
cells identified in the autoimmune attack during T1DM. Recently, Li et al. showed 
reduced hyperglycemia and increased serum insulin after intrapancreatic (iPan) 
transplantation of BM-derived MSC into STZ-treated rats(63). Together, these findings 
represent several independent cell types and unique mechanisms by which BM-derived 
cells can be used to induce endogenous islet regenerative processes. 
1.5.3 HSPC for Islet Regenerative Therapies 
BM-derived HSPC represent one of the most widely studied stem cell 
populations. These cells have the ability to self-renew and differentiate into all the 
lineages of the hematopoietic system. BM-HSPC are also believed to have proangiogenic 
effects, a trait that makes them a popular candidate for revascularization therapy and for 
use in patients with diabetes due to the high risk of vascular complications associated 
with the disease(62). CD34 is a cell surface marker encoding the saliomucin protein and is 
most widely known as a marker of human hematopoietic progenitor cells(64). Not only are 
CD34+ cells are rare to find in peripheral blood, cells that are positive rapidly lose 
expression of CD34 during in vitro expansion(65). However, HPSC isolated based on 
CD34 expression have shown the ability to reconstitute the hematopoietic system when 
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transplanted into sub lethally irradiated NOD/SCID mice. More recently, groups have 
been isolating HSPC that co-express different cell surface markers with or without CD34 
such as CD133, CD90, and CD49f, representing a more primitive hematopoietic cell for 
use in regenerative therapies(66, 67). This thesis focuses on identifying and expanding an 
islet regenerative hematopoietic stem progenitor cell (HSPC) population from UCB to 
mediate the induction of endogenous islet repair. 
1.5.4 Clinical Trials for Diabetes Using Cellular Therapies 
Voltarelli et al. performed the first reported clinical trial using HPSC 
transplantation into T1DM patients in 2007. Patients received high dose 
immunosuppressive therapies before taking cyclophosphamide and granulocyte colony 
stimulating factor. These agents act to mobilize HPSC into the peripheral blood so that 
they can be collected by apheresis for autologous transplantation(68). Interestingly, newly 
diagnosed T1DM patients receiving infusion of autologous apheresis product were able 
to prolong the requirement for exogenous insulin for 14.8 ± 11.2 months, and up to 35 
months in one case(69). Notably, GAD autoantibody levels were significantly decreased 6-
months post treatment, suggesting a dampening of autoimmunity. Mean cell number 
reinfused into patients using this autologous approach was 11.0 x 106 cells/kg body 
weight. Unfortunately, stem cell populations in patients with DM are often damaged or 
depleted due to chronic hyperglycemia, making autologous cell harvest and 
transplantation challenging. Results from this clinical trial suggested isolation of HSPC 
from a non-diabetic donor and expansion of healthy HPSC in vitro may be required to 
reach clinically applicable numbers for regeneration-inductive therapy. Thus, there is a 
need for HSPC from other sources such as UCB, followed by HSPC expansion. 
The biotechnology company Osiris Therapeutics, Inc. was approved for a phase II 
clinical trial using MSC from unrelated donors. Newly diagnosed T1DM patients (<20 
weeks from diagnosis) IV injected with Prochymal®, a mixture of BM-derived MSC 
from multiple donors that were cultured ex vivo for a minimum of 5 passages, as per good 
manufacturing practice (GMP) standards(70). The goal of the trial was to reduce 
inflammation in the pancreas and dampen the autoimmune attack found in T1DM, 
allowing pancreatic tissue to repair itself. 60 T1DM patients were enrolled in the study 
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and in 2012, Osiris Therapeutics released an update after the one year mark of the trial. 
Although no patients experienced a reaction from the IV injection of Prochymal®, there 
was no delay in progression of T1DM in the newly diagnosed patients. Unfortunately, c-
peptide levels between patients who received the active cell therapy and patients who 
received placebo were not significantly different and the trial has since been stopped(71). 
 Finally, in 2014, ViaCyte Inc. was approved for phase I/II clinical trials of their 
combination therapy (VC-01™) for T1DM patients. Their therapy combined the 
differentiation of human ES cells into committed pancreatic endoderm (PEC-01™) with 
Encaptra®, a device providing immunoprotection for transplanted cellular therapies(72). 
Notably, human ES cells were not differentiated into mature ß-cells prior to 
transplantation, but rather the completion of differentiation was to occur in vivo(73). 
Although the trial is still ongoing, there are expected to be many hurdles to overcome 
including ongoing rejection of the human ES cells, inefficient maturation of pancreatic 
endoderm progenitor cells to insulin producing ß-cells, and the lack of vasculature within 
and surrounding transplanted encapsulation devices to transport insulin to the 
periphery(74). 
1.6 Hematopoiesis and Hematopoietic Progenitor Cells 
Hematopoiesis is the process during embryology and continuing in adult life that 
forms the blood system of an organism. It is a highly conserved and regulated process 
and has been used as a model system to study the continual generation of mature effector 
cells in the hematopoietic system are typically short-lived. During embryogenesis, 
hematopoiesis begins in the aorta-gonad mesonephros region where the yolk sac 
develops. The fetal liver later takes over the process, finally ending in the BM where 
HSC are believed to reside at birth and remain throughout adult life(75). Immunodeficient 
mouse models such as the non-obese diabetic/severe combined immunodeficiency 
(NOD/SCID) mouse have been used to study the ability of HSC to reconstitute multiple 
lineages of the hematopoietic system (Figure 1.2)(76-78). Our understanding of 
hematopoiesis from these models has translated into astonishing treatments for cancers of 
the blood and aplastic anemia, primarily human BM transplants from HLA-matched 
donors(79, 80). 
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Figure 1.2. Postnatal hematopoietic hierarchy. Schematic showing the capacity of 
hematopoietic stem cells (HSC) to self-renew or differentiate towards maturity into the 
myeloid and lymphoid lineages. Cells lose aldehyde dehydrogenase activity, lose 
expression of primitive cell surface markers CD34 and CD133, and gain expression of 
mature hematopoietic cell surface marker CD38 as they differentiate. Multipotent 
progenitor (MPP); common myeloid progenitor (CMP); granulocyte-macrophage-
lymphocyte progenitor (GMLP); megakaryocyte-erythrocyte progenitor (MEP); 
granulocyte-macrophage progenitor (GMP); common lymphoid progenitor (CLP); 
natural killer (NK). 
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1.6.1 Cell Selection Using High Aldehyde Dehydrogenase Activity  
 As previously discussed, cell surface markers such as CD34 are classically used 
to isolate HSPC populations. CD34 has been well characterized as a marker of primitive 
hematopoietic progenitor cells and the loss of CD34 expression occurs as cells mature 
towards various hematopoietic lineages(81). There are; however, limitations to the use of 
cell surface markers to assess progenitor cell capacity. While CD34+ cell transition is 
typically conserved through hematopoiesis in vivo, CD34+ cell surface expression can 
vary as cells are manipulated ex vivo. Furthermore, Bhatia et al. reported a population of 
cells that were able to reconstitute hematopoiesis in SCID mice but were CD34-CD38-(57). 
This population has been further studied by Dominique Bonnet and John Dick’s labs, 
confirming a CD34- cell at the peak of the hematopoietic hierarchy(66, 67, 82). Thus, 
recently characterized functional markers may provide a more appropriate means of 
isolating true HSPC. 
High aldehyde dehydrogenase (ALDH) is a highly conserved function in 
primitive progenitor cells due to its role in eliminating reactive oxygen species from 
within cells. Thus, the cytoprotective role of ALDH allows for the isolation of multiple 
progenitor cell populations based on conserved enzymatic activity(83-85). Early progenitors 
that need to generate cells for the lifespan of the organism typically demonstrate high 
ALDH activity and as cells progress towards a more differentiated/expendable state, 
ALDH activity is reduced. In 2004, Hess et al. characterized the isolation of UCB-
derived HSC with high ALDH activity. This characterization used ALDH as a functional 
marker to isolate HSC that were able to repopulate irradiated NOD/SCID mice, providing 
an alternative method to isolation based on a beneficial progenitor function rather than 
cell surface marker expression(86, 87). 
There are 19 different isoforms of ALDH that have been identified in humans and 
this number being even greater in mice; however, the main isoform is ALDH1A1. 
Interestingly, hematopoiesis is seemingly unaffected in mice with a knockout in the 
Aldh1a1 gene(88). This finding lead researchers to study the compensatory role of other 
isoforms of ALDH in the absence of ALDH1A1. Studies in mice have shown that a 
deficiency in ALDH1A1 results in an increase in isoform ALDH3A1 in particular. 
  
18 
Gasparetto et al. have shown that a deficiency in both isoforms results in disrupted B-
lymphocyte maturation, increased reactive oxygen species, and a decrease in the total 
number of HSPC(89). Collectively, these findings help in characterizing the role of ALDH 
on HSPC and the hematopoietic hierarchy. 
1.6.2 Retinoic Acid Signaling 
Paradoxically, cytosolic ALDH also represents the rate limiting step in the 
production of retinoic acid (RA). RA is a morphogen, and the biologically active form of 
vitamin A. It has an important role during the development of many different organ 
systems and its transient expression is necessary for the proper differentiation of various 
cell types. In the context of hematopoiesis, RA is known to push differentiation down the 
hierarchy. In 1960, Breitman et al. studied the ability of RA to differentiate a cell line 
from a patient with acute promyelocytic leukemia (HL-60), suggesting that retinoids 
could be used therapeutically in patients with cancers of the blood(90). While mice with a 
knockout in their retinoic acid receptor (RAR) appeared to undergo hematopoiesis 
normally, it is widely believed that RA could have a role in hematopoietic lineage 
determination as cells mature(88). 
After ALDH converts the precursor retinal into biologically active RA, cytosolic 
retinoic acid binding protein (CRABP) binds to RA to aid with translocation to the 
nucleus. In canonical RA-signaling, RA binds to a heterodimer consisting of a retinoic 
acid receptor (RAR) and retinoid X receptor (RXR). Binding of RA to the heterodimer 
recruits a large co-activator complex that activates downstream gene transcription events. 
Thus, inhibition of canonical RA-signaling may prevent RA-induced differentiation of 
HSPC expanded ex vivo. 
1.6.3 Inhibition of Retinoid Signaling to Expand HSPC 
While ALDH can be used to identify and isolate primitive HSPC, Chute et al. set 
out to identify the role of ALDH in HSC differentiation and the loss of SCID 
repopulating capacity. DEAB, an inhibitor of ALDH, was used to expand HSPC in vitro 
and expression of target genes involved in HSC renewal such as Notch and HOXB4 was 
measured. When UCB-derived HSPC were expanded in serum-free culture and treated  
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with DEAB, there was a 3.4-fold increase in the number of SCID repopulating cells 
compared to day 0, representing a 7.7-fold increase compared to untreated conditions(91, 
92). These findings show that manipulating retinoid signaling in primitive hematopoietic 
cell populations can allow for the expansion of these rare cells while retaining high 
ALDH functional capacity. 
 There are several retinoid antagonists and inverse retinoid agonists that regulate 
retinoid signaling directly at the RAR/RXR heterodimer(93). In particular, this thesis 
focuses on the use of BMS 493, an inverse pan-RAR agonist, during the expansion of 
UCB-derived HSPC (Figure 1.3). Rather than acting as an antagonist and inhibiting the 
binding of RA to RARs, BMS 493 acts by binding allosterically and stabilizes a 
corepressor (CoR) complex at the heterodimer (Figure 1.4). These CoR complexes 
include repressive factors such as silencing mediator for retinoid and thyroid hormone 
receptors (SMRT) and nuclear receptor corepressor (NCoR). In addition, histone 
deacetylases are often found as part of these complexes, contributing to transcriptional 
silencing. BMS 493 is regarded as a more “powerful” inverse agonist than previously 
identified compounds due to its positioning and ability to act on all RAR subtypes. In 
contrast, a compound such as AGN109 only binds to RARγ, providing weaker repressive 
capabilities. While the structure and mechanism of action for BMS 493 have been 
identified, there are no studies that have used this compound in modulating retinoid 
signaling in the context of manipulating hematopoiesis or in the generation of HSPC for 
inducing islet regenerative therapies. 
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Figure 1.3 Chemical structure of inverse pan-RAR agonist, BMS 493. (E)-4-[2-
[5,6-Dihydro-5,5-dimethyl-8-(2-phenylethynyl)naphthalen-2-yl]ethen-1-yl]benzoic 
acid, 4-[(1E)-2-[5,6-Dihydro-5,5-dimethyl-8-(phenylethynyl)-2-
naphthalenyl]ethenyl]-benzoic acid, the chemical name for BMS 493, an inverse 
RAR agonist that allosterically binds to RARα, RARß, and RARg. 
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Figure 1.4. Mechanism of action for inverse pan-RAR agonist, BMS 493. BMS 493 
blocks canonical RA-signaling by allosterically binding the RAR. Binding to the RAR 
stabilizes a corepressor complex at the RAR/RXR heterodimer, leading to transcriptional 
silencing of downstream genes in the RA-pathway. 
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1.7 Transplantation of ALDHhi Cells to Induce Islet 
Regeneration 
Hess et al. showed that BM-derived cells expressing CD117 (c-kit) were able to 
reduce hyperglycemia when transplanted intravenously into STZ-treated NOD/SCID 
mice(57). These results suggested that BM-derived cells have the capacity to induce 
endogenous islet regeneration in damaged pancreatic tissue. In 2012, our lab published 
that UCB-derived cells isolated based on high ALDH activity were able to reduce STZ-
induced hyperglycemia in NOD/SCID mice after iPan transplantation(94). Both islet size 
and islet number were increased compared to ALDHlo and PBS controls, together, 
leading to increased ß-cell mass. Furthermore, serum insulin concentrations were 
increased and when given a glucose challenge (intraperitoneal glucose tolerance test), 
mice transplanted with ALDHhi cells had an improved response compared to ALDHlo 
cells and PBS controls. Collectively, these findings suggested that UCB-derived ALDHhi 
cells possess islet regenerative functions. 
To better understand the mechanisms behind endogenous islet regeneration, 
combinatorial intravenous transplantation of BM-derived MSC and UCB-derived 
ALDHhi cells were performed(95). While both MSC alone and MSC co-transplanted with 
ALDHhi cells showed increased ductal associated (measured by CK19), only co-
transplanted mice showed increased islet vessel density (measured by CD31 and vWF). 
Therefore, the authors suggested that MSC transplantation resulted in islet neogenesis 
while ALDHhi cell transplantation augmented the reduction in hyperglycemia by 
increasing vessel density and increasing ß-cell proliferation.  
Unfortunately, ALDHhi cells are rare, comprising <0.5% of all mononuclear cells 
in UCB. Thus, in order to reach clinically applicable numbers for the treatment of DM, ex 
vivo expansion without the loss of islet regenerative capacity is warranted. When UCB-
derived ALDHhi cells were expanded for 6 days in serum free conditions, ALDH activity 
rapidly declined as cells differentiated(96). When cells were reselected for high ALDH 
activity after 6-day expansion, there was a 3-fold increase in total ALDHhi cells available 
for transplantation. These cells retained high colony forming capacity and expression of 
primitive cell surface markers, suggesting they are phenotypically similar to uncultured 
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ALDHhi cells. Finally, 6-day expanded ALDHhi cells retained islet regenerative capacity 
and showed a reduction in hyperglycemia after IV transplantation into STZ-treated 
NOD/SCID mice. These findings acted as a proof-of-concept that UCB-derived ALDHhi 
cells could be expanded without the loss of endogenous islet regenerative functions. 
Thus, manipulation of pathways involved in hematopoietic cell differentiation such as the 
RA-pathway can be studied to further expand ALDHhi cells ex vivo and elucidate 
mechanisms involved in islet repair. This thesis focuses on the use of BMS 493, an 
inverse RAR agonist in expanding ALDHhi cells for use in islet regenerative therapies. 
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1.8 Objectives & Hypotheses 
The overall objective of this thesis was to characterize the expansion of UCB-derived, 
ALDHhi HSPC in serum-free culture conditions with or without the inverse retinoic acid 
receptor agonist, BMS 493. We also set out to establish whether BMS 493-treated, 
expanded could stimulate endogenous islet regeneration after intrapancreatic 
transplantation into STZ-treated, NOD/SCID mice. 
Compared to untreated expansion conditions, we hypothesized that expanded BMS 493-
treated HSPC will (1) retain a greater frequency of ALDHhi cells that co-express 
primitive cell surface markers, and (2) augment ß-cell survival and proliferation in vitro. 
Furthermore, we hypothesized that expanded BMS 493-treated cells will reduce 
hyperglycemia in STZ-treated NOD/SCID mice via the induction of endogenous islet 
proliferation and revascularization after intrapancreatic injection in vivo. 
These hypotheses were addressed by performing the following objectives: 
The first objective was to characterize RA-pathway inhibited cells after expansion using 
flow cytometry for the retention of high ALDH-activity and co-expression of primitive 
(CD34, CD133, CD117) and mature (CD38) hematopoietic cell surface markers. 
The second objective was to assess pro-survival and proliferation-stimulating effects of 
RA-pathway inhibited cells on human islets in vitro (conditioned media cultured with 
human islets). 
The third objective was to transplant RA-pathway inhibited cells and/or concentrated 
conditioned media into STZ-treated NOD/SCID mice to assess reduction of 
hyperglycemia after intrapancreatic transplantation. 
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2 Methods  
2.1 Blood Collection 
            Human UCB was collected with informed consent from the birthing centre at the 
London Health Sciences Centre, Victoria Hospital in London, Ontario under REB 12934. 
After caesarian sections, the umbilical cord was clamped and blood was drawn using a 16 
G needle coated in heparin (Novartis, Boucherville, CA) and 60 mL syringe by 
venipuncture. Samples were transported to our lab and processed to purify HSPC with 
high ALDH activity within 24 hours of collection 
2.2 Human Umbilical Cord Blood Processing 
Human UCB was processed as described in our lab’s previous publications(94-96). 
Briefly, RosetteSep™ Human Hematopoietic Progenitor Cell Enrichment Cocktail 
(StemCell Technologies, Vancouver, CA) was added to UCB at 5 µL/mL and incubated 
at room temperature for 30 minutes. Next, UCB was diluted with phosphate buffered 
saline (PBS, Invitrogen) prior to layering gently over Ficoll-Paque™ PLUS (GE 
Healthcare Life Sciences), and centrifuged at 450 relative centrifugal force (rcf) for 20 
minutes with the brake turned off. The lineage depleted mononuclear cell layer (Lin- 
MNC) was manually removed using a Pasteur pipette. Lin-MNC were washed with PBS 
supplemented with 5% fetal bovine serum (FBS) and cells were pelleted by 
centrifugation. Cells were resuspended in 1 mL PBS + 5% FBS and 9 mL Ammonium 
Chloride Solution (StemCell Technologies, Vancouver, CA) and incubated at room 
temperature for 7 minutes to lyse residual red blood cells. ells were washed, pelleted, and 
resuspended in ALDEFLUOR™ Assay Buffer (StemCell Technologies, Vancouver, CA) 
at 1 x 107 cells/mL. Next, cells were stained using ALDEFLUOR™ reagent (StemCell 
Technologies, Vancouver, CA) at 5 µL/mL and 5 x 105 cells were removed and treated 
with 5 µL N, N-diethylaminobenzaldehyde (DEAB), a reversible inhibitor of ALDH 
activity (StemCell Technologies, Vancouver, CA). ALDEFLUOR™-labeled sample and 
DEAB control were incubated at 37˚C for 30 minutes. Excess ALDEFLUOR™ substrate 
was removed by pelleting cells and resuspending in ALDEFLUOR™ Assay Buffer prior 
to fluorescent activated cell sorting (FACS) (FACSARIA III, BD BioSciences, 
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Missisauga, ON). Cells with high aldehyde dehydrogenase activity (ALDHhi cells) were 
purified using the DEAB control to identify ALDHlo cells and the ALDHhi cell gate was 
set at a fluorescence intensity approximately 2 times greater than the DEAB control. 
Purity of ALDHhi after FACS was reassessed at >95%. 
2.3 UCB ALDHhi Cell Expansion 
            12-well plates were coated with fibronectin from human plasma (Sigma-Aldrich, 
St. Louis, MO) prior to cell seeding. ALDHhi cells were plated at 2.5 x 104 cells/well in 
1.5 mL of serum-free, X-VIVO™ 15 media (Lonza, Basel, Switzerland) supplemented 
with 10 ng/mL each of thrombopoietin (TPO), stem cell factor (SCF), and FMS-related 
tyrosine kinase ligand (FLT-3L) (Gibco, Carlsbad, CA) and incubated at 37˚C(92). On day 
3, media was changed and cells were either left untreated or treated with 100 nM BMS 
493 (Sigma-Aldrich, St. Louis, MO).   
2.4 Cell Surface Marker Analyses 
            On day 6, cells were harvested and any adherent cells were lifted using 200 
µL/well TrypLE (Gibco, Carlsbad, CA). Cells were pelleted and resuspended in 
ALDEFLUOR™ Assay Buffer at 1 x 107 cells/ mL and stained with ALDEFLUOR™ 
reagent as previously described. After 30 minute ALDEFLUOR™ incubation, cells were 
washed, resuspended in ALDEFLUOR™ Assay Buffer, and labeled with the following 
fluorescent-tagged antibodies: 4 µL CD34-Brilliant Violet 421(BV 421), 2µL CD38-
phycoerythrobilin (PE), 4µL CD117-PE-CF594, and 4µL CD133-allophycocyanin (APC) 
at 4˚C for 20 minutes (all antibodies BD Pharminigen, San Diego, CA). After washing 
and centrifugation, samples were aspirated to leave ~400 µL and 3 µL of viability dye 7-
aminoactinomycin D (7-AAD) was added prior to being run on the BD LSR II Flow 
Cytometer (BD BioSciences, Missisauga, ON). UltraComp eBeads (eBioScience, San 
Diego, CA) were used for compensation controls on the BD LSR II Flow Cytometer and 
fluorescent minus one (FMO) controls as well as an unstained control were used to set 
gated populations. Flow cytometry data was analyzed using FlowJo software. 
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2.5 Methylcellulose Assay 
After 6-day expansion with or without BMS 493 treatment, unsorted (bulk) 
expanded cells or cell populations resorted for ALDH-activity were resuspended in 
Iscove’s Modified Dulbecco’s Medium (IMDM, Gibco, Carlsbad, CA) at 5 x 103 
cells/mL, and 900 µL of MethoCult™ (StemCell Technologies, Vancouver, CA) was 
added to 100 µL of cells using a 16 G needle with a 1 cc syringe. Cells were vortexed and 
incubated at room temperature for 8 minutes prior to being plated with 1 mL/ well in a 
12-well plate. Plates were incubated at 37˚C for 14 days prior to enumerating for 
hematopoietic colonies based on morphology for: blast forming unit-erythroid (BFU-E), 
colony forming unit-macrophage (CFU-M), colony forming unit-granulocyte (CFU-G), 
colony forming unit-granulocyte, monocyte (CFU-G), and colony forming unit-
granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM). 
2.6 Collection of HSPC Conditioned Media 
            After 6-day expansion with or without BMS 493-treatment, bulk HSPC were 
harvested and bulk populations were sorted using the FACSARIA III to select live cells 
based on their forward and side scatter parameters. Cells were plated at 2 x 105 cells/ mL 
in RPMI 1640 media (Gibco, Carlsbad, CA) supplemented with 10 ng/mL SCF, TPO, 
and FLT-3L. After 48 hours, conditioned media was collected and concentrated using a 3 
kilodalton Amicon Ultra-15 Centrifugal Filter Unit (Millipore, Billerica, MA). Cell 
viability was also recorded after 48 hours using the exclusion of trypan blue staining. 
2.7 Islet Culture with HSPC Conditioned Media  
            Purified and cultured human pancreatic islet samples from 4 individual donors 
were obtained through the Integrated Islet Distribution Program (IIDP, Duarte, CA). 200 
islet equivalents (IEQ) were plated per well in 6-well non-tissue culture treated 
suspension plates. Islets were initially plated in proprietary islet media (PIM) and topped 
up to 3 mL with RPMI 1640. After 24 hours, media was changed to RPMI supplemented 
with 10 ng/mL SCF, TPO, and FLT-3L. Islets were cultured for up to 7 days in RPMI 
supplemented with SCF, TPO, and FLT-3L (sub-optimal conditions), treated with 
conditioned media from cells expanded with or without BMS 493 (test conditions), or 
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treated with RPI supplemented with 10% FBS (optimal conditions). For 7-day culture 
experiments, 2 mL of each media was replaced on day 3 and islets were treated with 
additional conditioned media or FBS. 500 nM EdU (Invitrogen, Burlington, ON) was 
added to cultures on the final media change. On day 3 and 7, islets were collected and 
dissociated into a single cell suspension using TrypLE. Total cell number was manually 
counted using a hemocytometer and cells from each condition were divided and stained 
with 2 µL FluoZin-3 AM (Gibco, Carlsbad, CA), 4 µL Annexin V conjugated to BV 421, 
and 3 µL 7-AAD (viability dye) or fixed with 10% formalin and permeabilized with 1x 
saponin buffer prior to being stained with 10 µL anti-human insulin antibody conjugated 
to APC, 4 µL anti-human CD45 antibody conjugated to PE, and EdU click-it reaction 
conjugated to Alexa488 according to manufacturer’s specifications. 
2.8 In Vivo Transplantation Experiments 
Assessment of hyperglycemia reduction after intrapancreatic transplantation of 
expanded HSPC was performed as described in our previous publications under AUP 
2015-033(57, 94-96). Briefly, 7-8-week-old NOD/SCID mice (Jackson Laboratories, Bar 
Harbor, ME) were treated with 35 mg/kg/day of streptozotocin (STZ, Sigma, St. Louis, 
MO) for 5 consecutive days. Blood glucose was measured on day 10 and only mice with 
a blood glucose > 15 mmol/L (3 times greater than basal levels) were used for 
experiments. Expanded HSPC were harvested and resorted for ALDH activity using 
FACS. Bulk expanded cells or resorted ALDHhi or ALDHlo cell populations were 
transplanted by direct intrapancreatic injection using an insulin syringe on day 10 with 2 
x 105 cells/mouse in a total volume of 20 µL(94). Blood glucose was measured again on 
day 14, day 17, and weekly thereafter (day 21, 28, 35, and day 42). Area under the curve 
for unfasted blood glucoses was calculated over the 42-day time-course. 24 hours prior to 
euthanasia via cervical dislocation, mice were injected with 100 µL of 2.5 mg/mL EdU. 
Mice were also anesthetized using isoflurane and blood was collected via cardiac 
puncture and centrifuged to isolate serum. Pancreata were dissected from mice, weighed, 
and embedded in optimal cutting temperature medium (OCT, Sakura Finetec USA, 
Torrance, CA) blocks. Pancreas samples from each mouse were frozen, sectioned, and 
stained for quantification of ß-cell mass, islet vascularity, and human cell engraftment. 
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Pancreas samples from each mouse were cut into 10 µm serial sections with each slide 
having sections no less than 100 µm apart to prevent double counting islets. 
2.9 Immunohistochemistry & Quantification of ß-cell Mass 
Pancreas sections were fixed in 10% formalin (Thermo Fisher Scientific, Boston, 
MA) for 15 minutes and permeabilized with 1% Triton x-100 for 20 minutes. Basic 
mouse on mouse (M.O.M.) kit (Vector Laboratories, Burlington, ON) was used to block 
any nonspecific binding and to dilute the insulin antibody. Sections were stained with a 
mouse-specific insulin antibody (Sigma, St. Louis, MO) at 1:500 dilution, washed, and 
subsequently stained with peroxidase labeled anti-mouse IgG (Vector Laboratories, 
Burlington, ON) at 1:250 dilution. Slides were stained in DAB chromogen (Vector 
Laboratories, Burlington, ON) for 10 minutes and counterstained with hematoxylin. 
Finally, slides were mounted in VectaMount™ AQ (Vector Laboratories, Burlington, 
ON) before being imaged. Twelve images were taken per slide at 10 times magnification 
and islet number and circumference were calculated using Northern Eclipse Software. ß-
cell area was calculated using AxioVision software by encircling insulin+ area. Non-ß-
cell area was calculated by subtracting ß-cell area from total image area. ß-cell area/non-
ß-cell area was multiplied by the pancreas mass to calculate total ß-cell mass. 
2.10 Immunohistochemistry & Quantification of Islet 
Vascularization 
After fixation in formalin and blocking with M.O.M. kit as described above, 
pancreas sections were stained with mouse specific insulin antibody (Sigma, St. Louis, 
MO) at 1:500 dilution, washed, and subsequently stained with horse anti-mouse Texas 
Red (Vector Laboratories, Burlington, ON) at 1:200 dilution. Sections were washed and 
incubated in normal rabbit block (Vector Laboratories, Burlington, ON) for 1 hour prior 
to being co-stained with rat anti-mouse CD31 antibody (BD Pharminigen, San Diego, 
CA) for 30 minutes at 1:100 dilution and subsequently rabbit anti-rat fluorescein 
isothiocyanate (FITC) (Vector Laboratories, Burlington, ON) for 30 minutes at 1:200 
dilution and sections were mounted with VECTASHIELD® Mounting Medium (Vector 
Laboratories, Burlington, ON) and sealed. Images were taken of each islet within a 
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pancreas section at 20 times magnification. CD31+ cells were enumerated and total islet 
area was calculated using AxioVision software. 
2.11 Immunohistochemistry for Human Cell Engraftment 
Pancreas sections were fixed in formalin and blocked with M.O.M. kit as 
described in section 2.9. Sections were stained with mouse anti-human HLA-A,B,C 
antibody (BD Pharminigen, San Diego, CA), washed, and subsequently stained with 
horse anti-mouse FITC (Vector Laboratories, Burlington, ON). Sections were incubated 
in normal goat block (Vector Laboratories, Burlington, ON) for 1 hour prior to being co-
stained with rabbit anti-mouse insulin antibody (Abcam, Cambridge, UK) for 1 hour at 
1:50 dilution and subsequently being stained with goat anti-rabbit Texas Red (Vector 
Laboratories, Burlington, ON) for 20 minutes at 1:200 dilution. Sections were mounted 
with VECTASHIELD® Mounting Medium (Vector Laboratories, Burlington, ON) and 
sealed. 
2.12 Statistical Analyses 
Data is presented as mean ± standard error of the mean (SEM) unless indicated 
otherwise. Characterization of ALDH and primitive cell surface marker retention with or 
without BMS 493 treatment was analyzed using two-tailed student t-tests (*p< 0.05). 
Titration of BMS 493, AUC for in vivo data, and all histological data were analyzed using 
a one-way analysis of variance (ANOVA). 42 day blood glucose curves were analyzed 
using a two-way ANOVA with Tukey’s multiple comparisons test. Human islet culture 
data was analyzed using a two-way ANOVA with Dunnet’s multiple comparisons test. 
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3 Results 
3.1 BMS 493 Treatment Increased the Frequency of Cells 
with High ALDH Activity 
ALDHhi cells represent a rare (<0.5%) portion of UCB mononuclear cells. Thus, 
ex vivo expansion of this cell population is warranted to reach clinically applicable 
numbers for cellular therapies. Our lab and others have previously published a protocol 
for the ex vivo expansion of UCB-derived ALDHhi HSPC in clinically applicable, serum 
free media supplemented SCF, TPO, and FLT-3L(96-98). However, HSPC differentiate 
quickly in culture, reducing ALDH-activity, and resulting in the loss of islet regenerative 
function(96). Here, we utilized an inverse agonist of the retinoic acid receptor (RAR), 
BMS 493 to delay ALDHhi cell differentiation during culture, assessed by the 
preservation of high ALDH-activity. Using a 6-day expansion protocol, we tested various 
concentrations (10 nM – 500 nM) and duration of BMS 493 exposure to balance 
expansion efficiency with optimal retention of high ALDH activity. BMS 493-treatment 
at 100 nM from days 3-6 proved to be our best conditions as total cell expansion was 
equivalent for all parameters altered (Figure 3.1A-C) and 100nM from days 3-6 showed 
the greatest retention of ALDH activity (Figure 3.1D-F). Thus, BMS 493-treatment at 
100 nM from days 3-6, subsequently referred to as BMS 493-teratment, was selected as 
our optimal conditions for ALDHhi HSPC expansion. 
 
The commercially available ALDEFLUOR™ reagent can be used to measure 
ALDH activity levels in live cell populations using flow cytometry. DEAB, a reversible 
inhibitor of ALDH, was used to set a gate for cells with low ALDH activity and ALDHhi 
cell frequency was compared between BMS 493-treated and untreated cells (Figure 3.2A-
C).  While there was no significant difference in the total number of cells obtained after 
expansion with or without BMS 493-treatment (Figure 3.2D), the frequency of cells with 
high ALDH activity was significantly increased (p=0.001) after treatment with BMS 493 
(31.16 ± 3.09%) compared to untreated conditions (15.47 ± 1.92%) (Figure 3.2E). 
Collectively, 6-day expansion with 100 nM BMS 493-treatment from days 3-6 resulted in 
a 2.2-fold increase in total ALDHhi cells compared to untreated conditions (p=0.012),  
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Figure 3.1 Optimization of BMS 493-treatment based on retention of cells with high ALDH 
activity. Compared to untreated controls (N=12), total hematopoietic cell number at day 6 (fold 
increase versus day 0) was not altered by increasing concentrations of BMS 493-treatment from 
(A) days 0-6 (N=3-5), (B) days 0-3 (N=6-10), and (C) days 3-6 (N=3-8). On day 6, ALDHhi cell 
frequency was equivalent to untreated controls after BMS 493-treatment from (D) days 0-6 or 
(E) days 0-3. (F) In contrast, on day 6, ALDHhi cell frequency was increased after BMS 493-
treatment at 100 nM from days 3-6 compared to untreated controls. N represents different UCB 
donor samples. Data is shown as mean ± SEM (**p<0.01) determined by two-way ANOVA and 
Dunnett’s multiple comparisons test. 
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Figure 3.2 Treatment with BMS 493 increased ALDHhi cell frequency and total 
ALDHhi cell number after 6-day expansion. ALDH expression of expanded 
hematopoietic cell progeny was quantified at day 6 for: (A) DEAB-treated control, (B) 
untreated conditions (N=12) and (C) treatment with BMS 493 (N=8). (D) Total cell 
number obtained with BMS 493 treatment was equal to untreated controls. However, BMS 
493 treatment showed (E) increased ALDHhi cell frequency and (F) total ALDHhi cell 
number compared to untreated conditions (fold increase versus day 0). N represents 
different UCB donor samples. Data is shown as mean ± SEM (*p<0.05, ***p<0.001) 
determined by two-tailed student t-test. 
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resulting in an 8.3 ± 1.27-fold increase in ALDHhi cells compared to the cell number 
initially plated (Figure 3.2F). 
3.2 BMS 493-Treated ALDHhi Cells Retained Primitive Cell 
Surface Marker Expression 
Expression of primitive cell surface markers CD34, CD133, and CD117 was 
assessed by flow cytometry on expanded cells with or without BMS 493-treatment. 
Representative flow cytometry dot plots (Figure 3.3A and B) demonstrated similar CD34 
and CD133 expression between BMS 493-treated and untreated cells with high ALDH 
activity. Although cells treated with BMS 493 showed no difference in the frequency of 
ALDHhi cells co-expressing CD34 (p=0.610) and CD133+ (p=0.443) cells at day 6 
(Figure 3.3C and D), treatment with BMS 493 resulted in 1.89 and 1.86 times more 
ALDHhiCD34+ (p=0.002) and ALDHhiCD133+ (p=0.004) cells, respectively, a significant 
increase compared to untreated conditions (Figure 3.3E and F).  Cells were also assessed 
for expression of c-kit (CD117), a marker previously shown to be expressed on murine 
BM cells that play a role in pancreatic regeneration(57). There was no significant 
difference in the frequency or total number of ALDHhiCD117+ cells after 6-day 
expansion as compared to untreated conditions (data not shown). Thus, BMS 493-
treatment preserved primitive CD34 and CD133 expression on cells retaining high 
ALDH activity. 
Conversely, expanded cells were also assessed for CD38 expression, an early 
indicator of CD34+ cell differentiation, and a marker of hematopoietic maturation(99). 
Representative flow cytometry dot plots (Figure 3.4A and B) demonstrated decreased CD 
38 expression when comparing BMS 493-treated and untreated ALDHhi cells.  Cells 
treated with BMS 493 showed a significant decrease in the frequency of ALDHhiCD38+ 
cells 1.82 ± 0.59% as compared to 16.40 ± 4.45% in untreated samples (p=0.010) (Figure 
3.4C). Total ALDHhiCD38+ cell number was significantly decreased showing 48.50 times 
decrease in expression (p=0.013) compared to untreated cells (Figure 3.4D).  
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Figure 3.3 Treatment with BMS 493 increased total ALDHhi CD34+ cells and 
ALDHhi CD133+ after 6-day expansion. Representative flow cytometry dot plots 
showing CD34 and CD133 expression on ALDHhi hematopoietic cells from: (A) 
untreated (N= 10) and (B) BMS 493-treated (N=7) conditions. Compared to untreated 
controls, BMS 493-treated cells showed an equivalent frequency of (C) primitive 
ALDHhi CD34+ cells and (D) ALDHhi CD133+ cells. However, since high ALDH activity 
was better retained under BMS 493-treated conditions, the total number of (E) primitive 
ALDHhi CD34+ and (F) ALDHhi CD133+ cells were increased (fold increase versus day 
0). N represents different UCB donor samples. Data is shown as mean ± SEM (**p<0.01) 
determined by two-tailed student t-test. 
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Figure 3.4 Treatment with BMS 493 decreased total ALDHhiCD38+ cell frequency 
and total cell number after 6-day expansion. Representative flow cytometry dot plots 
showing CD38 expression on ALDHhi hematopoietic cells from: (A) untreated controls 
(N=10) and (B) treatment with BMS 493 (N=7). Compared to untreated controls, BMS 
493-treated cells showed a decrease in (C) mature ALDHhiCD38+ frequency and (D) 
total ALDHhiCD38+ cells (fold increase versus day 0). N represents different UCB donor 
samples. Data is shown as mean ± SEM (*p<0.05, **p<0.01) determined by two-tailed 
student t-test. 
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3.3 Colony Forming Capacity Was Retained After BMS 493 
Treatment 
Myeloid colony formation in methylcellulose media was used to test for 
hematopoietic progenitor cell function after 6-day expansion. In general, colony forming 
capacity is decreased with prolonged culture. The frequency of total hematopoietic 
colony formation was equal between untreated and BMS 493-treated cells (Figure 3.5A). 
When different lineages of hematopoietic colonies were compared, there was also no 
significant difference in the frequency of colony subtypes between BMS 493-treated cells 
and untreated controls (Figure 3.5B). After resorting based on ALDH activity, the 
number of colony forming units (CFUs) per 100 cells was significantly greater (p=0.002) 
in the ALDHhi subpopulation than the ALDHlo subpopulation of both BMS 493-treated 
cells (9.80 ± 1.67 and 4.55% ± 0.96 respectively) and untreated controls (12.30% ± 0.90 
and 5.22% ± 0.54 respectively) after 6-day expansion (Figure 3.5C). When different 
lineages of hematopoietic colonies were compared between the resorted populations, 
there was no significant difference in the frequency of colony subtypes between BMS 
493-treated populations and untreated controls (Table 3.1). Ultimately, treatment with 
BMS 493 during increased the total number of ALDHhi cells available for transplantation 
without the loss of hematopoietic colony forming capacity. 
 
 
 
 
 
 
  
39 
 
Untreated BMS 493
0
5
10
15
CF
U
/ 1
00
 c
el
ls
1 2 3 4 5
0
1
2
3
4
# 
of
 C
ol
on
ie
s/ 
10
0 
Ce
lls
BFU-E           CFU-G         CFU-M         CFU-GM      CFU-Mixed
0
5
10
15
CF
U
/1
00
 C
el
ls
****
*
Un
tre
ate
d
AL
DH
hi
Un
tre
ate
d
AL
DH
lo
BM
S 4
93
AL
DH
hi
BM
S 4
93
AL
DH
lo
A B 
C 
Figure 3.5 Treatment with BMS 493 retained ALDHhi HSPC colony forming capacity 
after 6-day expansion. Compared to untreated controls (N=4, performed in duplicate), BMS 
493-treated cells (N=6, performed in duplicate) showed (A) no difference in colony forming 
capacity after enumeration of hematopoietic colonies in methylcellulose. (B) BMS 493-treated 
cells produced equal number of BFU-E, CFU-G, CFU-M, CFU-GM, or CFU-GEMM as 
untreated controls. (C) After expanded cells were resorted based on ALDH activity, ALDHhi 
subpopulations of BMS 493-treated (N=4, performed in duplicate) cells and untreated control 
cells (N=6, performed in duplicate) formed more colonies than their respective ALDHlo cells. N 
represents different UCB donor samples. Data is shown as mean ± SEM (*p<0.05, ***p<0.001) 
determined by two-tailed student t-test (A) or one-way ANOVA (B, C). 
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Table 3.1. Analyses of hematopoietic colony subtypes produced by BMS 493-treated 
cells and untreated controls resorted based on ALDH-activity. 
 
 
After 6-day expansion, BMS 493-treated ALDHhi and ALDHlo hematopoietic cell subsets 
produced an equal number of BFU-E, CFU-G, CFU-M, CFU-GM, or CFU-GEMM as 
compared to respective untreated ALDHhi and ALDHlo cells. Data is shown as mean ± 
SEM with analysis of significance determined by one-way ANOVA. 
 
 
 
 
 
 
 
 
 
 
Untreated 
ALDHhi 
(CFU/100 cells) 
Untreated 
ALDHlo 
(CFU/100 cells) 
BMS 493-treated 
ALDHhi 
(CFU/100 cells) 
BMS 493-treated 
ALDHlo 
(CFU/100 cells) 
BFU-E 4.77 ± 0.83 1.18 ± 0.35 3.78 ± 1.59 2.00 ± 0.84 
CFU-G 1.65 ± 0.30 1.75 ± 0.29 1.60 ± 0.32 0.88 ± 0.27 
CFU-M 1.43 ± 0.38 0.65 ± 0.16 1.05 ± 0.34 0.73 ± 0.14 
CFU-GM 1.70 ± 0.54 0.73 ± 0.17 1.30 ± 0.18 0.48 ± 0.19 
CFU-GEMM 2.75 ± 0.90 0.90 ± 0.25 2.08 ± 0.55 0.48 ± 0.21 
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3.4 Transplantation of Expanded Cells Did Not Reduce 
Hyperglycemia in STZ-Treated NOD/SCID Mice 
We tested the ability of BMS 493-treated cells to reduce hyperglycemia after 
intrapancreatic transplantation into STZ-treated NOD/SCID mice. Fresh UCB-derived 
ALDHhi cells not cultured in vitro were transplanted as a positive control to replicate data 
published using our established mouse model (Figure 3.6A)(57, 94, 95). BMS 493-treated 
cells did not significantly (p=0.460) reduce hyperglycemia over 42 days as compared to 
PBS controls (Figure 3.6B). Area under the curve of blood glucose curves over 42 days 
showed no significant reduction in blood glucose over time between transplantation of 
BMS 493-treated cells (p=0.998) or untreated cells (p=0.593) compared to PBS controls 
(Figure 3.6C). However, area under the curve of blood glucose values over 42 days was 
significantly reduced (p=0.002) when fresh ALDHhi cells were iPan transplanted as 
compared to PBS controls (Figure 3.6C). 
Islet size, islet number, and ß-cell mass were also quantified for each mouse using 
histological pancreas sections from mice transplanted with BMS 493-treated cells, 
untreated cells, or PBS controls post-mortem. Representative photomicrographs for each 
cohort are shown in Figure 3.7A. Mice transplanted with BMS 493-treated cells or 
untreated cells showed no significant difference in average islet size (p=0.051), islet 
number (p=0.755), or ß-cell mass (p=0.521) as compared to PBS controls (Figure 3.7B-
D). Pancreas sections from transplanted mice were also stained with platelet endothelial 
cell adhesion molecule (PECAM-1, CD31) to assess potential changes in islet vascularity 
(Figure 3.8A). Mice transplanted with BMS 493-treated cells or untreated cells showed 
no significant difference (p=0.319) in the number of CD31+ cells per islet area as 
compared to PBS controls (Figure 3.8B). Collectively, these data indicate that islet 
regenerative capacity was diminished by 6-day culture with or without BMS 493 
treatment. 
It has been previously published that expanded cells resorted based on high 
ALDH activity were able to reduce hyperglycemia after IV transplantation into STZ-
treated NOD/SCID mice(96). Therefore, we resorted BMS 493-treated cells and untreated 
cells based on ALDH activity after expansion and tested their ability to reduce 
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hyperglycemia after iPan transplantation. There was no significant change in 
hyperglycemia over 42 days after transplantation of BMS 493-treated ALDHhi (p=0.080), 
BMS 493-treated ALDHlo (p=0.978), untreated ALDHhi (p=0.207), or untreated ALDHlo 
(p=0.929) cells as compared to PBS controls (Figure 3.9A). Area under the curve of 
blood glucose curves over 42 days showed no significant change in blood glucose over 
time between transplantation of BMS 493-treated ALDHhi (p=0.441), BMS 493-treated 
ALDHlo (p=0.999), untreated ALDHhi (p=0.903), or untreated ALDHlo (p=0.999) cells as 
compared to PBS controls (Figure 3.9B). Thus, unlike IV transplantation, resorting 
expanded cells for high ALDH activity did not show retained islet regenerative capacity 
after iPan transplantation.  
 Islet size, islet number, and ß-cell mass were quantified after transplantation of 
resorted populations from BMS 493-treated and untreated cells (Figure 3.10A). 
Compared to PBS controls, there was no significant difference in average islet size 
(p=0.607), islet number (p=0.406), or ß-cell mass (p=0.697) after transplantation of 
ALDHhi and ALDHlo subpopulations from resorted BMS 493-treated or untreated cells 
(Figure 3.10B-D). Furthermore, CD31 expression was also quantified in pancreas 
sections from mice transplanted with BMS 493-treated or untreated cells resorted based 
on ALDH activity (Figure 3.11A). Mice transplanted with resorted subpopulations from 
BMS 493-treated or untreated cells showed no significant difference (p=0.335) in the 
number of CD31+ cells per islet area as compared to PBS controls (Figure 3.11B). Islet 
vascularity is not improved by resorting of expanded cell populations based on a 
primitive progenitor function, ALDH activity. 
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Figure 3.6 Expanded cells did not reduce hyperglycemia after iPan transplantation into 
STZ-treated NOD/SCID mice. (A) Schematic showing timeline of STZ treatments, iPan 
transplantation, and blood glucose measurements in NOD/SCID mice. (B) Transplantation of 
BMS 493-treated cells (n= 6) or untreated cells (n=5) did not reduce hyperglycemia over 42 days 
as compared to PBS controls (n=8). Transplantation of fresh ALDHhi cells (n=4) reduced 
hyperglycemia at day 35 compared to PBS controls. (C) Area under the curve for blood glucose 
concentration over 42 days showed no reduction in hyperglycemia over time after transplantation 
of BMS 493-treated or untreated cells compared to PBS controls. In contrast, transplantation of 
fresh ALDHhi cells reduced area under the curve of glucose curves over 42 days compared to 
PBS controls. n represents individual experimental mice. Data is shown as mean ± SEM 
(*p<0.05, **p<0.01) determined by two-way ANOVA (B) and one-way ANOVA (C) with 
Tukey’s multiple comparisons test. 
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Figure 3.7 Expanded cells did not alter difference in islet size, islet number, or ß-cell 
mass after iPan transplantation into STZ-treated NOD/SCID mice. (A) Representative 
photomicrographs of pancreas sections from mice transplanted with PBS controls, untreated 
expanded hematopoietic cells, or BMS 493-treated hematopoietic cells. Mice transplanted 
with untreated (n=5) or BMS 493-treated (n=6) cells showed no difference in islet size (B), 
islet number (C), or ß-cell mass (D) as compared to PBS controls (n=8). n represents 
individual experimental mice. n represents individual experimental mice. Data is shown as 
mean ± SEM with analysis of significance determined by one-way ANOVA. 
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Figure 3.8 Expanded cells did not alter islet vascularity after iPan transplantation into 
STZ-treated NOD/SCID mice. Representative pancreas immunohistochemistry sections 
showing insulin and CD31 from mice transplanted with (A) PBS, untreated expanded 
hematopoietic cells, or BMS 493-treated hematopoietic cells. (B) BMS 493-treated (n=3) or 
untreated (n=3) cells showed no difference in CD31+ cells/µm islet area as compared to 
PBS controls (n=3). n represents individual experimental mice.  Data is shown as mean ± 
SEM with analysis of significance determined by one-way ANOVA. 
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Figure 3.9 Expanded hematopoietic cells resorted based on ALDH activity did not 
reduce hyperglycemia after iPan transplantation into STZ-treated NOD/SCID mice. 
(A) Transplantation of BMS 493-treated ALDHhi (n=4), BMS 493-treated ALDHlo (n=4), 
untreated ALDHhi (n=4) or untreated ALDHlo (n=4) cells ALDHhi did not reduce 
hyperglycemia over 42 days as compared to PBS controls (n=8). (B) Area under the curve 
of blood glucose curves over 42 days after transplantation of resorted BMS 493-treated or 
untreated cell populations showed no reduction in blood glucose over time compared to 
PBS controls. n represents individual experimental mice. Data is shown as mean ± SEM 
with analysis of significance determined by two-way ANOVA (A) and one-way ANOVA 
(B). 
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Figure 3.100 Expanded hematopoietic cells resorted based on ALDH activity did not 
alter islet size, islet number, or ß-cell mass after iPan transplantation into STZ-treated 
NOD/SCID mice. (A) Representative photomicrographs of pancreas sections from mice 
transplanted with untreated ALDHhi, untreated ALDHlo, BMS 493-treated ALDHhi, or BMS 
493-treated ALDHlo cells. Mice transplanted with BMS 493-treated ALDHhi (n=4), BMS 
493-treated ALDHlo (n=4), untreated ALDHhi (n=4) or untreated ALDHlo (n=4) cells showed 
no significant difference in islet size (B), islet number (C), or ß-cell mass (D) as compared to 
PBS controls (n=8). n represents individual experimental mice. Data is shown as mean ± 
SEM with analysis of significance determined by one-way ANOVA. 
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Figure 3.111 Expanded hematopoietic cells resorted based on ALDH activity did 
not alter islet vascularity after intrapancreatic transplantation into STZ-treated 
NOD/SCID mice. (A) Representative immunohistochemistry sections of mouse 
pancreas showing insulin and CD31 after intrapancreatic transplantation of untreated 
ALDHhi, untreated ALDHlo, BMS 493-treated ALDHhi, or BMS 493-treated ALDHlo 
cells. (B) Mice transplanted with BMS 493-treated ALDHhi (n=3), BMS 493-treated 
ALDHlo (n= 3), untreated ALDHhi (n=3) or untreated ALDHlo (n=3) cells showed no 
significant difference in difference in CD31+ cells/µm islet area as compared to PBS 
controls (n=3). n represents individual experimental mice. Data is shown as mean ± SEM 
with analysis of significance determined by one-way ANOVA. 
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3.5 Conditioned Media from BMS 493-Treated Cells 
Increased ß-Cell Proliferation In Vitro 
Next, human islets were cultured with CM generated from HSPC expanded with 
or without BMS 493 and assessed for ß-cell survival and proliferation via flow 
cytometry. Representative photopictomicrographs are shown on day 3 for human islets 
cultured with CM from BMS 493-treated cells, CM from untreated controls, and media 
controls (RPMI 1640) (Figure 3.12A). Islets cultured in CM generated from untreated or 
BMS 493-treated cells showed no significant difference (p=0.642) in total islet cell 
number at both day 3 and day 7 as compared to media controls (Figure 3.12B). FluoZin-3 
AM is an indicator of zinc (Zn2+) and was used to mark intact ß-cells, which are high in 
zinc due to the exocytosis machinery of secretory granules containing insulin(100). Islets 
cultured in CM generated from untreated or BMS 493-treated cells did not change the 
frequency of FluoZin-3+ cells (p=0.717) or permeabilized CD45-Insulin+ cells (p=0.858) 
compared to media controls, both used as indicators of ß-cell frequency between 
conditions (Figure 3.12C and D). Thus, treatment of human islets with CM generated 
from expanded cells did not affect total cell number or ß-cell number after 3 or 7 days in 
vitro. 
The viability dye 7-AAD and apoptosis marker Annexin V were used to assess ß-
cell survival via flow cytometry. Representative flow cytometry dot plots are shown for a 
fluorescence-minus-one (FMO) control used to set a FluoZin-3+ gate, an experimental 
condition showing FluoZin-3+ cells, and Annexin V versus 7-AAD, showing cell 
apoptosis and cell death frequencies on FluoZin-3+ cells specifically (Figure 3.13A-C). 
CM from untreated or BMS 493-treated cells did not alter the frequency of live ß-cells 
(Q4:FluoZin-3+7AAD-Annexin-, p=0.730), apoptotic ß-cells (Q3:FluoZin-3+7AAD-
Annexin+, p=0.864), dead ß-cells (Q2:FluoZin-3+7AAD+Annexin+, p=0.546), and 
necrotic ß-cells (Q1:FluoZin-3+7AAD+Annexin-, p=0.755) at both day 3 and day 7 as 
compared to media controls (Figure 3.13D-G). CM generated from expanded cells did 
not change the frequencies of apoptosis or survival of human ß-cells after 3 or 7 days in 
culture. 
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Figure 3.122 Human islets cultured with conditioned media generated from BMS 
493-treated hematopoietic cells showed no difference in frequency of ß-cells. (A) 
Representative photopictomicrographs showing human islets cultured with CM 
generated from BMS 493-treated cells, untreated controls, or media controls (RPMI 
1640) on day 3. (B) Compared to media controls (N=3), CM from BMS 493-treated cells 
(N=3-4) or untreated controls (N=3-4) showed no differences in total cell number at day 
3 or day 7. Compared to media controls, CM from BMS 493-treated cells or untreated 
controls showed no difference in frequency of (C) FluoZin-3+ cells or (D) CD45-Insulin+ 
cells at day 3 or day 7. N represents individual pancreas donors. Data is shown as mean ± 
SEM with analysis of significance determined by repeated measures ANOVA. 
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Figure 3.133 Human islets cultured with conditioned media generated from BMS 493-
treated hematopoietic cells showed no difference in ß-cells survival. Representative flow 
cytometry dot plots showing (A) FMO control used to set FluoZin-3+ gate, (B) FluoZin-3+ 
gated on experimental samples (C) Annexin V against 7-AAD to assess apoptosis and cell 
death on FluoZin-3+ cells. Compared to media controls (RPMI 1640, N=3), CM from BMS 
493-treated cells (N=3-4) or untreated cells (N=3-4) showed no differences in the frequency 
of (D) Annexin V-7AAD- (live) ß-cells, (E) Annexin V+7AAD- (apoptotic) ß-cells, (F) 
Annexin+7AAD+ (dead) ß-cells, and (G) Annexin-7AAD+ (necrotic) ß-cells at day 3 or day 
7. N represents individual pancreas donors. Data is shown as mean ± SEM with analysis of 
significance determined by two-way ANOVA. 
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Figure 3.144 Human islets cultured with conditioned media generated from BMS 493-
treated hematopoietic cells showed an increase in the number of proliferating ß-cells. 
Representative flow cytometry dot plots showing (A) gating CD45- cells to eliminate 
hematopoietic contamination, (B) insulin+ gate to mark ß-cells, and (C) EdU gated on 
insulin+ cells to mark proliferating ß-cells. (D) Compared to media controls (RPMI 1640, 
N=3), CM from BMS 493-treated cells (N=3-4) or untreated cells (N=3-4) showed no 
difference in the frequency of EdU+ ß-cells at day 3 or day 7. (E) CM from BMS 493-treated 
cells showed an increase in the total number of EdU+ ß-cells at both day 3 and day 7 
compared to CM from untreated cells and media controls. N represents individual pancreas 
donors.  Data is shown as mean ± SEM (*p<0.05) determined by two-way ANOVA and 
Dunnett’s multiple comparisons test. 
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Incorporation of EdU, a thymine analog, was used to assess the induction of ß-cell 
proliferation via flow cytometry. Representative flow cytometry dot plots show exclusion 
of hematopoietic contamination using negative gating for CD45+ cells, insulin was used 
to mark permeabilized ß-cells, and EdU analyses was gated on insulin+ cells to mark 
proliferating ß-cells (Figure 3.14A-C). CM from untreated or BMS 493-treated cells 
showed no significant difference (p=0.695) in the frequency of proliferating ß-cells 
(CD45-Insulin+EdU+) at both day 3 and day 7 as compared to media controls (Figure 
3.14D). However, when total proliferating ß-cells were enumerated, islets cultured with 
CM generated from BMS 493-treated cells showed a significant increase in the total 
number of proliferating ß-cells at both day 3 (p=0.037) and day 7 (p=0. 035) as compared 
to media controls (Figure 3.14E). CM generated from ALDHhi cell expansion with BMS 
493 induced human ß-cell proliferation in vitro. 
3.6 Conditioned Media Generated from Expanded Cells Did 
Not Reduce Hyperglycemia in STZ-Treated NOD/SCID 
Mice 
Following the increase in ß-cell proliferation shown when human islets were 
cultured with CM generated from BMS 493-treated cells in vitro, we injected CM from 
BMS 493-treated or untreated cells directly into the pancreata of STZ-treated NOD/SCID 
mice. Unpublished data from our lab has shown that iPan injection of CM generated from 
cultured human MSC consistently reduce hyperglycemia in STZ-treated NOD/SCID 
mice (Kuljanin et al.). However, iPan injection of protein concentration-matched CM 
from BMS 493-treated or untreated cells did not significantly (p=0.272) reduce 
hyperglycemia over 42 days as compared to media (RPMI 1640) controls (Figure 3.15A). 
Area under the curve of blood glucose curves over 42 days confirmed no significant 
reduction in blood glucose was observed after injection of CM from BMS 493-treated 
cells (p=0.221) or untreated cells (p=0.157) compared to media controls (Figure 3.15B). 
Finally, islet size, islet number, and ß-cell mass were quantified using histological 
pancreas sections post-mortem from mice injected with CM generated from BMS 493-
treated cells, untreated cells, or transplanted with media controls (Figure 3.16A). As 
indicated by the evaluation of hyperglycemia, mice injected with CM from BMS 493-
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treated or untreated cells showed no significant difference in average islet size (p=0.248), 
islet number (p=0.535), or ß-cell mass (p=0.589) compared to media controls (Figure 
3.16B-D). Thus, injection of concentrated CM from expanded cells into STZ-treated 
NOD/SCID mice showed no reduction in hyperglycemia and no effect on ß-cell mass. 
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Figure 3.155 Conditioned media from BMS 493-treated cells showed no difference in 
islet size, islet number, or ß-cell mass after iPan injection into STZ-treated 
NOD/SCID mice. (A) Injection of CM from BMS 493-treated cells (n=4) or untreated 
cells (n=3) did not reduce hyperglycemia over 42 days as compared to media (RPMI 1640) 
controls (n=3). (B) Area under the curve of blood glucose curves over 42 days showed no 
reduction in blood glucose over time after injection of CM from BMS 493-treated or 
untreated cells compared to media controls. n represents individual experimental mice. 
Data is shown as mean ± SEM with analysis of significance determined by two-way 
ANOVA (A) and one-way ANOVA (B). 
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Figure 3.166 Conditioned media from BMS 493-treated hematopoietic cells showed no 
difference in islet size, islet number, or ß-cell mass after iPan injection into STZ-treated 
NOD/SCID mice. (A) Representative photomicrographs of pancreas sections from mice 
injected with media (RPMI 1640) controls, CM from untreated cells, or CM from BMS 493-
treated cells. Mice injected with CM from BMS 493-treated (n=4) or untreated (n=3) cells 
showed no difference in islet size (B), islet number (C), or ß-cell mass (D) as compared to 
media controls (n=3). n represents individual experimental mice.  Data is shown as mean ± 
SEM with analysis of significance determined by one-way ANOVA. 
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4 Discussion 
4.1 Retinoid Signaling in the Expansion of Hematopoietic 
Progenitor Cells  
Previously, we have identified that a subset of UCB-derived cells with high 
ALDH activity can stimulate endogenous islet repair after iPan transplantation into 
NOD/SCID mice with STZ-induced hyperglycemia(94). However, these cells are 
extremely rare, representing <0.5% of UCB mononuclear cells and thus, ex vivo 
expansion of this cell population with minimal differentiation is warranted to generate 
sufficient cell numbers for islet regenerative cell therapy(101). Unfortunately, HSPC 
differentiate quickly when cultured, rapidly losing their high ALDH activity after 6-day 
expansion(96). UCB ALDHhi cells were expanded under clinically applicable, serum free 
culture conditions with cytokine supplementation; however, only 15.4 ± 1.9% of cells 
retained high ALDH activity after 6-day expansion(92). Chute et al. suggested that 
inhibition of retinoid signaling during HSPC expansion could prevent RA-induced 
differentiation towards maturity down the hematopoietic hierarchy(91). By using DEAB 
during short term culture, a direct inhibitor of ALDH1, Chute showed increased number 
of CD34+CD38-Lin- cells compared to day 0. Expanded cell progeny had increased 
number of SCID repopulating cells after transplantation into NOD/SCID mice. Finally, 
DEAB-treatment showed decreased expression of cEBPε, a downstream target of RAR-
signaling. Our lab has used a similar strategy to expand ALDHhi cells with DEAB to 
prevent differentiation for use in vascular regenerative therapies (Cooper et al.). Thus, 
alternate molecules such as BMS 493 to block RA-induced differentiation are needed to 
develop allogeneic cell therapy approaches for diabetes and its comorbidities. 
The first aim of this thesis was to characterize the expansion of ALDHhi cells in 
culture under hematopoietic cell-specific conditions, using a small molecule inhibitor of 
retinoic acid signaling. BMS 493 is an inverse pan-RAR agonist that, when bound to the 
RAR/RXR heterodimer, stabilizes a corepressor complex, silencing downstream gene 
transcription(93). When treated with BMS 493, UCB-derived ALDHhi progeny expanded 
for 6 days in culture showed a 2-fold increase (31.16 ± 3.09%) in the frequency of cells 
with high ALDH activity compared to untreated controls. These cells also retained 
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expression of primitive cell surface markers CD34 and CD133 and had reduced 
expression of the mature hematopoietic cell surface marker CD38. Treatment with BMS 
493 did not reduce the enhanced colony forming capacity of the ALDHhi subset compared 
to ALDHlo subset of cell progeny. Despite preservation of primitive HSPC phenotype, 
cell proliferation over 6 days was not inhibited by BMS 493 treatment. Therefore, 
treatment with BMS 493 during the 6-day expansion of ALDHhi cells resulted in an 8.3 ± 
1.27-fold increase in the total number of cells available for transplantation, without the 
loss of primitive cell phenotype. 
ALDH activity represents the rate-limiting step in the conversion of vitamin A to 
retinoic acid, a powerful morphogen. Presumably, by inhibiting ALDH during HSPC 
expansion using DEAB, Chute et al. reduced the total amount of RA available for 
downstream signaling. In contrast, BMS 493 acts further downstream on the RAR/RXR 
heterodimer required for RA-pathway targeted gene transcription. Since BMS 493 does 
not directly affect the production of RA in the cell, levels of RA are likely unaffected or 
even slightly increased. Consequently, RA accumulation in the cytosol would be 
available to non-canonical RA signaling pathways not impacted by the RAR/RXR 
heterodimer, acting as a ligand for less common receptors such as receptor-related orphan 
receptors (RORß)(102). Since RA is a morphogen, levels regularly fluctuate in cells and 
are difficult to accurately measure. Measurement of downstream targets of RA signaling 
pathways may help elucidate how manipulating the actions of RA during ex vivo culture 
affects the differentiation and regenerative capacity of HSPC. 
4.2 Islet Regenerative Capacity of Uncultured and Cultured 
Cell Populations 
In the context of cell therapies for diabetes, several preclinical studies have used 
hematopoietic mononuclear cells or MSC, primarily from human BM, to induce 
endogenous islet regeneration in situ. Bell et al. showed that BM-derived stem cells 
isolated based on high ALDH activity can reduce hyperglycemia after IV injection into 
STZ-treated NOD/SCID mice(95). In 2012, our lab published that direct iPan delivery of 
uncultured, UCB-derived ALDHhi cells could reduce hyperglycemia and increase serum 
insulin levels in STZ-treated NOD/SCID mice. Furthermore, mice showed improved 
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functional recovery when tested using a glucose challenge (intraperitoneal glucose 
tolerance test) compared to mice injected with an equivalent dose of ALDHlo cells or 
PBS controls(94). HLA+ cells were detected surrounding islets at days 14 and 17, although 
few were detected up to day 42. Although the mechanism of repair was not fully 
established, HLA+ cells detected never co-expressed insulin, suggesting that the donor 
cells induced endogenous islet repair in the hosts via undetermined paracrine activities. 
The authors proposed that increased exposure of the pancreas to regenerative factors 
secreted by ALDHhi cells ultimately enhanced the regenerative response in vivo. 
Unfortunately, iPan transplantation of UCB-derived ALDHhi cells expanded in culture 
lost their ability to reduce hyperglycemia in the same mouse model, with or without BMS 
493-treatment. Thus, while HSPC can be expanded efficiently ex vivo, secretory and pro-
survival function may be compromised by culture induced differentiation and 
transplantation at higher cell doses may be required to achieve a regenerative effect after 
intravenous or direct intrapancreatic injection. 
4.3 Intrapancreatic Versus Intravenous Delivery of 
Expanded Hematopoietic Progenitor Cells 
Following the reduction in hyperglycemia after iPan transplantation of uncultured 
UCB-derived ALDHhi cells into STZ-treated NOD/SCID mice, iPan injection was 
selected as the preferred method of delivery for cells expanded under RA-pathway 
inhibited conditions. Our lab had previously extended these findings to show expanded 
cells reselected for high ALDH activity possess similar regenerative function after IV 
injection of cells(96). Interestingly, only the ALDHhi fraction of expanded cells showed 
consistent engraftment in the BM after IV transplantation as measured by CD45+ and 
HLA-A,B,C+ cells using flow cytometry. However, iPan injection of expanded HSPC 
treated with or without BMS 493 that were resorted based on high ALDH activity after 6 
days did not show a reduction in hyperglycemia. Although IV-injection of cells expanded 
with BMS 493 was not assessed in this thesis, it is likely that the regenerative effect of 
cells is dependent on the proteins they secrete and how these signaling molecules interact 
with other cell types found in the host pancreas. While iPan transplantation is a more 
direct mode of transporting these signaling molecules to the site of tissue injury than IV 
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transplantation, human cell survival and engraftment may be compromised since the 
STZ-treated pancreas is a suboptimal niche for expanded HSPC and only small volumes 
can be transplanted into the murine pancreas without risk of damage to the exocrine 
tissue or pancreatitis. Therefore, it is important to characterize parameters such as human 
cell survival and engraftment along with tissue regeneration and functional recovery 
when determining the optimal mode of delivery for cell therapy in patients with DM. 
4.4 Importance of Islet Vascularization in Insulin Delivery 
The pancreas, like other endocrine organs, is extremely well vascularized. The 
ability for the pancreas to develop during embryogenesis as well as perform its role 
through adult life is dependent on adequate supply of blood. In particular, maintenance of 
normoglycemia relies on the transport of insulin from the islets of Langerhans to 
peripheral tissues in the body. First described in the 1800s, islets have their own capillary 
networks that are glomerular-like and can take up as much as 10% of the total islet 
volume(103, 104). In addition, islets are approximately 10 times more vascular than their 
surrounding exocrine tissue, even though they only make up a small proportion of the 
pancreas, and vascularization of islets is considered independent of exocrine pancreas 
vascularization. Replacing lost ß-cell mass in T1DM may be the primary goal of new 
cellular therapies; however, ensuring proper vascularization of ß-cells is imperative in 
achieving functional recovery and glucose homeostasis. 
 While little is known regarding the mechanisms of islet regeneration after 
expanded ALDHhi cell transplantation, there is a larger body of literature studying the 
pro-angiogenic effects of HSPC in models of vascular injury. Our lab has previously 
shown that UCB-derived ALDHhi cells can aid in the revascularization and perfusion of 
injured muscle tissue after femoral artery ligation in NOD/SCID mice, an important 
finding given the prevalence of peripheral artery disease and critical limb ischemia as a 
complication of DM(101). When UCB ALDHhi cells were in noncontact co-culture with 
human umbilical vein endothelial cells (HUVEC) in serum free media, only ALDHhi cells 
increased viability of HUVEC compared to ALDHlo cells or HUVEC grown alone. 
Furthermore, co-culture of UCB ALDHhi cells and HUVEC in Matrigel showed 
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increased formation of tube-like structures after 24 hours compared to co-culture with 
ALDHlo cells. Collectively, these findings showed that UCB-derived ALDHhi cells 
contained hematopoietic and endothelial progenitor cell populations that played a role in 
revascularization and increased capillary density when transplanted after ischemic injury. 
Surprisingly, the ability of UCB-derived ALDHhi cell progeny to revascularize the 
hind limb after femoral artery ligation was not lost after ALDHhi cells were expanded for 
6 days in culture (105). Expanded ALDHhi cells did not require reselection after expansion 
to potently augment limb revascularization after femoral artery ligation. Proliferation of 
host CD31+ endothelial cells was detected post-mortem and microarray analysis of 
expanded HSPC showed increased transcription of several pro-angiogenic cytokines 
including vascular endothelial growth factors (VEGF-A and VEGF-B) as well as 
angiopoietin-1 and epidermal growth factor. These findings suggest that HSPC play a 
vital role in revascularization of ischemic tissue and that these results could be translated 
to use UCB-derived ALDHhi cells in revascularizing injured pancreatic tissue. 
 Combinatorial transplantation of regenerative BM-derived MSC followed by 
uncultured UCB-derived cells showed a greater reduction in hyperglycemia in STZ-
treated NOD/SCID mice than either cell population independently(57, 94, 95). One 
explanation of these results is that while both populations work synergistically to increase 
ß-cell mass by inducing endogenous islet repair, the HSPC are able to further improve the 
reduction in hyperglycemia by better vascularizing the islets and improving the transport 
of insulin outside of the pancreas. Upon further investigation, immunohistochemistry 
showed that transplantation of regenerative MSC alone or in combination with ALDHhi 
cells resulted in increased ductal association with islets but only MSC in combination 
with ALDHhi cells caused increased vessel density. It was proposed that transplantation 
of MSC induced islet neogenesis while transplantation of UCB-derived ALDHhi cells was 
pro-angiogenic, inducing ß-cell proliferation. Although we did not see differences in the 
frequency of CD31+ cells found in islets after iPan transplantation of HSPC expanded 
with BMS 493, this may have been due to the fact that ß-cell mass was not increased. 
Thus, vascularization was not induced since there was insufficient insulin production 
after STZ treatment to warrant new vasculature for transport. While we did not observe a 
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reduction in hyperglycemia from iPan transplantation of expanded HSPC alone, 
expansion of this cell population with small molecules such as BMS 493 may be 
important to revascularize islets after an alternate regenerative stimulus is delivered, 
particularly in islet replacement strategies that focus on increasing the number of ß-cells 
available and survival of ß-cells after transplantation. 
4.5 Conditioned Media as a Regenerative Therapeutic 
Conditioned media (CM) represents the heterogeneous secretome of cells grown 
in culture that can be collected and concentrated to study its composition and functional 
capacity. CM contains a mixture of proteins, signaling lipid molecules, and microRNAs 
that may be packaged within extracellular vesicles and can be released into the 
circulation to augment endogenous regenerative capacity without having to transplant the 
cells that the CM is generated from(106). Deriving therapeutic agents using CM has several 
advantages compared to cellular therapies. One of the most important of these advantages 
is that without the transplant of live cells, donor matching and immune rejection can be 
bypassed. Second, the ability to identify individual factors or mixture of factors involved 
in the regeneration processes can provide a streamlined approach to efficiently develop 
novel therapeutics using modern proteomic techniques. Finally, mechanisms of 
regeneration can be better understood and established without the interplay of donor and 
host cells. 
With these advantages in mind, we derived a model to test the effects of CM 
exposure on the survival and proliferation of primary human islets obtained through the 
Integrated Islet Distribution Program using flow cytometry on dispersed islets. Our lab 
previously published that CM collected from Wnt pathway-activated MSC augmented the 
total ß-cell number, frequency of live ß-cells, and frequency of proliferating ß-cells(107). 
While no differences in ß-cell survival were found, CM collected from BMS 493-treated 
HSPC increased the number of proliferating ß-cells in vitro. This lead us to further study 
the effects of CM on islet regeneration after iPan transplantation of concentrated CM into 
STZ-treated NOD/SCID mice. Transplantation of CM was predicted to be a potent 
therapy because CM can be concentrated using filtration units and transplanted directly 
into the mouse pancreas using low volumes. Transplantation of CM generated from 
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expanded HSPC treated with BMS 493 did not show a reduction in hyperglycemia or 
increased ß-cell mass in STZ-treated mice. In contrast to our in vitro human islet cultures 
that showed an increase in ß-cell proliferation, these effects may not have been replicated 
in vivo due to extensive ß-cell damage as a result of STZ-treatment. Our in vitro culture 
system utilized cadaveric islets from non-diabetic donors and thus signaling mechanisms 
may differ between the healthy and diabetic pancreas microenvironments.  
 
4.6 Clinical Implications 
Currently, one of the limiting factors to developing novel cellular therapies for the 
treatment of T1DM is the availability of an unlimited source of ß-cells. While preclinical 
findings have extensively studied the differentiation of hES and iPS cells into mature, 
glucose-responsive ß-cells, the safety and efficacy of these sources for use in cellular 
therapies remains unclear. UCB provides a readily available source of multipotent HPSC 
that have previously shown islet regenerative functions in preclinical trials(94, 95). 
However, cells that harness regenerative capacity are rare in postnatal tissue, such as 
UCB, and differentiate quickly when expanded ex vivo(96, 105). In order to reach clinically 
applicable numbers to treat patients with T1DM, cell expansion, without the loss of 
regenerative function, will be necessary. In 2012, as a platform for the treatment of blood 
disorders including leukemia, Csazar et al. published important findings relevant to 
hematopoietic cell expansion. By using a batch-fed bioreactor system, large scale ex vivo 
expansion was made possible by controlled media dilution, thus minimizing the 
inhibitory feedback that cultured cells are exposed to over time(97). Other agents are being 
investigated for their effect on self-renewal and differentiation of stem cells during ex 
vivo culture. For example, agents that inhibit the aryl hydrocarbon receptor such as the 
compound UM729 showed decreased differentiation of acute myeloid leukemia cells in 
culture(108). While our previously described culture conditions are serum free and thus 
clinically applicable, these findings act as proof-of-concept that ex vivo expanded cells 
can maintain their regenerative capacity. These findings become more powerful for 
clinical use when combined with large scale bioreactor systems such as the fed-batch 
system described by Csazar. Thus, bioreactor technologies for expansion, combined with 
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pharmacological manipulation of the cell product, provides a powerful strategy for the 
development of cell therapies. 
Regenerating lost ß-cell mass is only the first step in developing a curative 
therapy for T1DM. Relentless continued autoimmune attack in patients with T1DM 
represents another challenge for the implementation of curative strategies. Ongoing 
clinical trials have made use of bioengineered encapsulation devices that allow 
transplanted cells to secrete insulin to the periphery while protecting donor cells from the 
host immune system. Furthermore, while donor cells inside encapsulation devices have 
shown promising results and the ability to secrete insulin outside the device, 
vascularization of these devices by the host may be a difficult obstacle to overcome. 
Given the pro-angiogenic effect of UCB-derived ALDHhi cells, expansion of this 
population for transplantation inside encapsulation devices alongside insulin-producing 
donor cells could induce endogenous vascularization of the device by the host. 
Additionally, BM-derived MSC are a popular candidate for cellular therapies for T1DM 
given their immunomodulatory capabilities. These properties of MSC are currently under 
investigation in both preclinical and clinical trials and may be used to protect donor cells 
from the autoimmune attack found in T1DM patients(109, 110). Thus, a combination of 
regenerative cell types and strategies such as bioengineered encapsulation devices may 
facilitate the development of cell therapy for T1DM patients in the face of autoimmunity. 
Another obstacle in the development of any cell therapy, irrespective of the 
autoimmunity in T1DM, is rejection of donor cells by the host immune system. One 
strategy we studied to overcome continued cell rejection was to inject CM generated 
from regenerative cell populations into our hyperglycemic mouse model. CM was 
hypothesized to harness the regenerative capacity of our expanded HSPC by 
concentrating secreted proteins that mediate endogenous islet repair without the need for 
cell transfer. CM can also be delivered systematically or at the site of tissue injury, 
allowing for the induction of important signaling pathways in regenerative cells. 
Likewise, issues regarding transdifferentiation and tumor formation that are often raised 
with transplantation of hES and iPS cells are alleviated by use of CM. Although use of 
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CM in clinical therapies is a relatively new concept, preclinical evidence has shown 
immense potential for future use. 
While we did not observe a reduction in hyperglycemia or increased ß-cell mass 
after transplantation of our expanded cell populations, these cells may harness other 
important regenerative capabilities. For example, cardiovascular complications as a result 
of chronic hyperglycemia in both T1DM and T2DM patients are an immense 
socioeconomic burden. Our lab previously published that expanded HSPC derived from 
UCB have potential for reperfusion of ischemic tissue, an important finding in relation to 
peripheral artery disease faced by many DM patients. Although culture-expanded HSPC 
may not stimulate ß-cell recovery and function as hypothesized, there remains a huge 
potential for the use of expanded ALDHhi cells for improvement of associated 
complications, resulting in increased life expectancy. 
4.7 Study Limitations & Future Directions 
In the future, studies can be performed to further understand the mechanism of 
action for BMS 493 when used during the expansion of HSPC. Since RA is a lipid 
morphogen, we were unable to measure the levels of RA quantitatively using available 
techniques such as flow cytometry. However, mass spectrometry of RA levels should be 
performed during expansion. Other techniques such as ChIP or qRT-PCR can also be 
used to measure the activity of RA-signaling. For example, downstream targets of 
canonical RA-signaling such as HOXA1 and CYP26A1 can be measured using qRT-PCR 
and effective inhibition of RA-signaling using BMS 493 is expected to show a decrease 
in predicted targets(111). Better understanding of how BMS 493 modulates RA-signaling 
pathways and thus, delaying differentiation of HSPC as observed by cell surface marker 
analyses, is important to efficiently expand these cells to clinically applicable numbers.   
Human islets in culture were treated with CM generated from expanded HSPC to 
test their effect on the survival and proliferation of human ß-cells. However, one 
limitation to our study was that human islets in culture were from non-diabetic donors 
and were cultured in media with approximately 11 mM of glucose. Since ß-cells make up 
the majority of the cells within the islets of Langerhans, it is difficult to isolate intact 
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islets from patients with T1DM. In contrast, larger differences in survival and 
proliferation may be seen if islets are exposed to injury. For example, islets from non-
diabetic donors could be cultured in media with glucose levels greater than 11 mM, better 
mimicking the hyperglycemic environment found in both T1DM and T2DM patients. 
Additionally, other damaging stimuli such as oxidative stress and lipid toxicity could be 
used to better represent the injured pancreas in patients with DM. Furthermore, signaling 
mechanisms for endogenous islet regeneration may not be present or may be dampened 
when healthy, undamaged islets are treated with either regenerative cells or CM.  
Our lab previously showed that expanded ALDHhi cells resorted after culture 
reduce hyperglycemia after IV transplantation into STZ-induced hyperglycemic 
NOD/SCID mice. However, in these studies, the same population was unable to reduce 
hyperglycemia after iPan transplantation. Another limitation to our study was that we 
were unable to perform histological analyses directly after iPan transplantation since all 
mice were sacrificed after 42 days. Future experiments may be conducted to look at 
human cell survival and engraftment at earlier time points (days 14 or 17) to elucidate 
differences between the two modes of cell delivery, as reduced cell survival in the 
pancreas microenvironment could truncate the regenerative response. Both flow 
cytometry and immunohistochemistry should be used to identify the engraftment and 
survival patterns of HLA-A,BC+ cells after transplantation. While iPan transplantation 
was predicted to be a more direct method of transplanting cells with regenerative 
capabilities at the site of tissue injury, it may not be the most clinically applicable as it is 
more invasive than IV transplantation. Future experiments to compare and contrast iPan 
and IV transplantation with expanded cell populations is important for developing 
cellular therapies in the future. 
Finally, CM generated from HSPC expanded with BMS 493 showed increased 
human ß-cell proliferation in vitro. However, iPan transplantation of CM from expanded 
cell populations into STZ-treated NOD/SCID mice showed no differences in ß-cell mass. 
Proteomic analysis of the composition of CM can help determine specific factors and 
their roles in islet regeneration. Isolating specific factors may also help to explain the 
different mechanisms that influence ß-cell proliferation in vitro and in vivo.  
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4.8 Summary and Conclusions 
In summary, diabetes mellitus is a complex metabolic disease and current 
treatment options including exogenous insulin therapy and oral medications are 
inadequate. Chronic hyperglycemia found in patients with DM leads to dramatically 
increased risk of cardiovascular disease and several other co-morbidities, ultimately 
lowering the life expectancy of patients with DM. UCB-derived ALDHhi cells have 
previously been shown to induce endogenous islet regeneration in NOD/SCID mice with 
STZ-induced hyperglycemia. However, this cell population is extremely rare (<0.5% of 
UCB mononuclear cells) and thus ex vivo expansion is warranted to reach clinically 
applicable cell numbers. Unfortunately, ALDHhi cells differentiate rapidly in culture 
losing their ALDH activity and regenerative capacity over time. In this thesis, we used 
BMS 493, an inverse RAR agonist, to inhibit RA-induced differentiation of UCB-derived 
ALDHhi cells in culture. After 6 days, BMS 493-treated ALDHhi cells showed a 2-fold 
increase in cells that retained high ALDH activity without the loss of primitive cell 
surface marker (CD34 and CD133) expression or colony forming capacity. Treating 
human islets in culture with CM generated from BMS 493-treated ALDHhi cells showed 
increased ß-cell proliferation. Intrapancreatic delivery of cell progeny after expansion of 
ALDHhi cells with or without BMS 493 showed no reduction in hyperglycemia after 
transplantation into STZ-treated NOD/SCID mice. Thus, UCB-derived ALDHhi cells lose 
their islet regenerative capacity during ex vivo expansion. Future studies are warranted to 
investigate the potential pro-angiogenic role of expanded HSPC and their use in 
combination with other cell types for the development of novel cell therapies in the 
treatment of DM. 
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